METHODS AND DIAGNOSTIC KITS UTILIZING MAMMALIAN STRESS PROMOTERS TO DETERMINE TOXICITY OF A COMPOUND

This invention provides methods and diagnostic kits for identifying and characterizing toxic compounds. These methods and diagnostic kits measure transcription or translation levels from genes linked to native eukaryotic stress promoters, especially those of mammals. The kits and methods of this invention utilize at least one stress promoter from each of the following groups: redox stress, DNA stress, protein stress and energetic/ionic stress. The invention also provides methods and diagnostic kits for identifying and characterizing compounds that are toxic to specific organs, such as skin and the eye, as well as for each of the individual stresses indicated above. The methods and diagnostic kits of this invention yield information concerning the action of a compound on a subcellular level. This information may be utilized to design antitoxins to compounds found to be toxic and in active drug design.
### FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

<table>
<thead>
<tr>
<th>AT</th>
<th>Austria</th>
<th>GB</th>
<th>United Kingdom</th>
</tr>
</thead>
<tbody>
<tr>
<td>AU</td>
<td>Australia</td>
<td>GE</td>
<td>Georgia</td>
</tr>
<tr>
<td>BB</td>
<td>Barbados</td>
<td>GN</td>
<td>Guinea</td>
</tr>
<tr>
<td>BE</td>
<td>Belgium</td>
<td>GR</td>
<td>Greece</td>
</tr>
<tr>
<td>BF</td>
<td>Burkina Faso</td>
<td>HU</td>
<td>Hungary</td>
</tr>
<tr>
<td>BG</td>
<td>Bulgaria</td>
<td>IE</td>
<td>Ireland</td>
</tr>
<tr>
<td>BJ</td>
<td>Benin</td>
<td>IT</td>
<td>Italy</td>
</tr>
<tr>
<td>BR</td>
<td>Brazil</td>
<td>JP</td>
<td>Japan</td>
</tr>
<tr>
<td>BY</td>
<td>Belarus</td>
<td>KE</td>
<td>Kenya</td>
</tr>
<tr>
<td>CA</td>
<td>Canada</td>
<td>KG</td>
<td>Kyrgyzstan</td>
</tr>
<tr>
<td>CF</td>
<td>Central African Republic</td>
<td>KP</td>
<td>Democratic People's Republic</td>
</tr>
<tr>
<td>CG</td>
<td>Congo</td>
<td>KR</td>
<td>Republic of Korea</td>
</tr>
<tr>
<td>CH</td>
<td>Switzerland</td>
<td>KZ</td>
<td>Kazakhstan</td>
</tr>
<tr>
<td>CI</td>
<td>Côte d'Ivoire</td>
<td>LI</td>
<td>Liechtenstein</td>
</tr>
<tr>
<td>CM</td>
<td>Cameroon</td>
<td>LK</td>
<td>Sri Lanka</td>
</tr>
<tr>
<td>CN</td>
<td>China</td>
<td>LU</td>
<td>Luxembourg</td>
</tr>
<tr>
<td>CS</td>
<td>Czechoslovakia</td>
<td>LV</td>
<td>Latvia</td>
</tr>
<tr>
<td>CZ</td>
<td>Czech Republic</td>
<td>MC</td>
<td>Monaco</td>
</tr>
<tr>
<td>DE</td>
<td>Germany</td>
<td>MD</td>
<td>Republic of Moldova</td>
</tr>
<tr>
<td>DK</td>
<td>Denmark</td>
<td>MG</td>
<td>Madagascar</td>
</tr>
<tr>
<td>ES</td>
<td>Spain</td>
<td>ML</td>
<td>Mali</td>
</tr>
<tr>
<td>FI</td>
<td>Finland</td>
<td>MN</td>
<td>Mongolia</td>
</tr>
<tr>
<td>FR</td>
<td>France</td>
<td>MR</td>
<td>Mauritania</td>
</tr>
<tr>
<td>GA</td>
<td>Gabon</td>
<td>MW</td>
<td>Malawi</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NE</td>
<td>Niger</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NL</td>
<td>Netherlands</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO</td>
<td>Norway</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NZ</td>
<td>New Zealand</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PL</td>
<td>Poland</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT</td>
<td>Portugal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RO</td>
<td>Romania</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU</td>
<td>Russian Federation</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SD</td>
<td>Sudan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SE</td>
<td>Sweden</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SI</td>
<td>Slovenia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SK</td>
<td>Slovakia</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SN</td>
<td>Senegal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TD</td>
<td>Chad</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TG</td>
<td>Togo</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TJ</td>
<td>Tajikistan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TT</td>
<td>Trinidad and Tobago</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UA</td>
<td>Ukraine</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US</td>
<td>United States of America</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UZ</td>
<td>Uzbekistan</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VN</td>
<td>Viet Nam</td>
</tr>
</tbody>
</table>
METHODS AND DIAGNOSTIC KITS UTILIZING MAMMALIAN
STRESS PROMOTERS TO DETERMINE TOXICITY OF A COMPOUND

TECHNICAL FIELD OF INVENTION

This invention provides methods and diagnostic kits for identifying and characterizing toxic compounds. These methods and diagnostic kits measure transcription or translation levels from genes linked to native eukaryotic stress promoters, especially those of mammals. The kits and methods of this invention utilize at least one stress promoter from each of the following groups: redox stress, DNA stress, protein stress and energy/ionic stress. The invention also provides methods and diagnostic kits for identifying and characterizing compounds that are toxic to specific organs, such as skin and the eye, as well as for each of the individual stresses indicated above. The methods and diagnostic kits of this invention yield information concerning the action of a compound on a subcellular level. This information may be utilized to design antitoxins to compounds found to be toxic and in active drug design.

BACKGROUND OF THE INVENTION

At least 55,000 chemicals are presently produced in the United States. Over 2,000 new chemicals are introduced into the market each year. Very few of these chemicals have been comprehensively tested for acute or chronic toxicity. For example, less than 1 percent of commercial chemicals have undergone complete health hazard assessment.

The Environmental Protection Agency ("EPA") has the authority to require toxicological testing of a chemical prior to commercial production, but that authority is rarely invoked. Less than 10 percent of new chemicals are subjected to detailed review by the
EPA. In the interest of cost and speedy access to the market, the EPA often uses the toxicity of previously tested homologous compounds to gauge the toxicity of a new chemical.

The potential toxicity of new drugs is monitored by the Food and Drug Administration ("FDA"). For a New Drug Application (NDA), the FDA typically requires a large battery of toxicity, carcinogenicity, mutagenicity and reproduction/fertility tests in at least two species of live animals. These tests are required to last up to one year. A two year toxicity test in rats costs approximately $800,000 [Casarett and Doull's Toxicology, 4th Edition, M. O. Amdur et al., eds. Pergamon Press, New York, New York, p. 37 (1991)].

Besides cost, animal testing also presents disadvantages in terms of time, animal suffering and accuracy. Typical toxicity tests are divided into three stages: acute, short term and long term. Acute tests, which determine the LD$_{50}$ of a compound (the dose at which 50% of test animals are killed), require some 60-100 animals and a battery of tests for determining LD$_{50}$, dose-response curves and for monitoring clinical end points, other than death. Short term tests usually involve at least 24 dogs and 90 rats and last from 90 days in rats to 6-24 months in dogs. Body weight, food consumption, blood, urine and tissue samples are frequently measured in the short-term tests. In addition, dead animals are subjected to post-mortem examinations. Long term tests are similar to short term tests, but last 2 years in rats and up to 7 years in dogs or monkeys.

Animal testing has come under criticism by animal rights activists and the general public because of the severe suffering inflicted on the animals. Moreover, recent evidence calls into question the accuracy of animal testing. For example, variables,
such as animal diet, may impair the predictability of animal tests in determining carcinogenic properties [P. H. Abelson, "Diet and Cancer in Humans and Rodents", *Science*, 255, p. 141 (1992)]. And prior determinations on dioxin toxicity, based on guinea pig testing, are now being reevaluated [B. J. Culliton, "US Government Orders New Look At Dioxin", *Nature*, 352, p. 753 (1991); L. Roberts, "More Pieces in the Dioxin Puzzle", *Research News*, October, 1991, p. 377]. It is therefore apparent that there is an urgent need for a quick, inexpensive and reliable alternative to toxicity testing in animals.

Several short-term alternative tests are available. For example, the Ames Assay detects carcinogens which cause genetic reversion of mutant strains of *Salmonella typhimurium*. However, the Ames Assay cannot detect either non-mutagenic carcinogens or non-carcinogenic toxins. The yeast carcinogen assay system described in United States patent 4,997,757 overcomes some of the drawbacks of the Ames Assay, but is still not able to detect non-carcinogenic toxins. Both of these assays are designed to detect alterations and mutations at the DNA level only. Therefore, those prior art tests cannot detect direct damage to proteins or lipid membranes, nor inhibitors of DNA synthesis. Moreover, those prior art tests cannot provide information as to how a mutagen or toxin exerts its effect.

Applicant's copending United States application Serial No. 910,793, filed July 6, 1992, the disclosure of which is herein incorporated by reference, describes an assay system which utilizes a reporter gene fused to bacterial stress promoters to determine and characterize the toxicity of a compound. This assay is able to detect damage to proteins or lipid membranes and inhibition of DNA synthesis. Thus,
this assay provides for the identification of non-
carcinogenic toxins. Unfortunately, the correlation
between bacterial toxicity and toxicity to mammals and
other higher eukaryotes has certain limitations and may
not be an accurate measure of toxicity in higher
animals.

Therefore, there is still a need for an assay
that has the time and cost-saving features of the
bacterial stress assay, but is based on a eukaryotic
cell.

**SUMMARY OF THE INVENTION**

Applicant has fulfilled this need by
providing an *in vitro* diagnostic kit and assay method
which identify and characterize the cellular and sub-
cellular effect of a potential toxin on an animal cell.
These kits and methods employ the native stress
promoters of eukaryotic cells, preferably mammalian
cells, and measure the level of transcription or
translation of a gene which is operatively linked
thereto. Depending upon the choice of stress promoters
used, the kits and methods of this invention may be
designed to identify and characterize compounds that
are toxic to the whole animal or to specific organs of
that animal.

In one embodiment, the kits and methods of
this invention characterize the toxicity of a compound
by determining the level of transcription of various
stress genes present in a eukaryotic cell. These kits
and methods employ oligonucleotides that are
complementary or homologous to at least a portion of
various stress gene messenger RNAs to detect
transcription of those genes in the cell. In this
embodiment a single cell is effectively an *in vivo*
diagnostic reagent for determining what particular
stress a given compound induces.
In another embodiment, each of a plurality of similar eukaryotic cells harbors a different stress promoter operatively linked to a reporter gene. By exposing each cell separately to a compound and measuring the expression of the reporter gene product, the toxicity of that compound may be characterized.

The kits and methods of this invention are optimally designed to determine the toxicity of a compound in a matter of days, rather than the months or years required for animal testing. Furthermore, the kits of this invention achieve these results for a fraction of the cost of animal testing and without the objectionable consequences to live animals. And, the diagnostic kits and methods of this invention yield direct information about the nature of a toxin's action on mammalian cells -- something that the prior art short-term assays fail to do.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of tetrachlorodibenzo-p-dioxin (TCDD).

Figure 2 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of 3-methyl cholangthrene (3-MC).

Figure 3 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of benzo[a]pyrene.

Figure 4 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of cadmium sulfate.
Figure 5 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of dimethyl sulfoxide (DMSO).

Figure 6 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of ethanol.

Figure 7 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of methapyrilene hydrochloride.

Figure 8 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of methyl methanesulfonic acid (MMS).

Figure 9 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of sodium arsenate.

Figure 10 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of phorbol 12-acetate-13-myristate (PMA).

Figure 11 depicts the relative expression of chloramphenicol acetyl transferase under the control of different stress promoters in the presence of varying concentrations of retinoic acid.

**DETAILED DESCRIPTION OF THE INVENTION**

As used herein, the terms "stress" and "toxicity" are used interchangeably and refer to the disturbance of the biochemical and biophysical homeostasis of the cell.
The term "redox stress", as used throughout this application, refers to conditions which vary from the normal reduction/oxidation potential ("redox") state of the cell. Redox stress includes increased levels of superoxides radicals, increased levels of peroxides -- both hydrogen peroxide and organic peroxides --, decreased levels of glutathione and any other conditions which alter the redox potential of the cell, such as exposure to strong reducing agents, some aromatic hydrocarbons, electrophilic compounds, aldehydes, intracellular thiols, steroids, methyl cholanethrene, phenobarbital and CCl₄. The term also includes any additional conditions which cause proliferation of peroxisomes.

The term "DNA stress", as used herein, refers to alterations to deoxyribonucleic acid or to precursor nucleotides. For example, DNA stress includes, but is not limited to, DNA strand breaks, DNA strand cross-linking, exposure to DNA intercalating agents, both increased and decreased superhelicity, oxidative DNA damage, DNA alkylation, oxidation of nucleotide triphosphates and alkylation of nucleotide triphosphates. The term also includes inhibition of DNA synthesis and replication and inhibition of mitosis or meiosis. And the term includes conditions caused by exposure to growth factors, interferons, tumor promoters, tumor necrosis factor, phorbol esters, hydrophobic cytotoxic drugs, inflammatory agents, mitogens, carcinogens, X-rays, UV radiation and dimethylNitrosamines.

"Protein stress", as used throughout the application, refers to alterations to proteins or individual amino acids and inhibition of enzyme functions, as well as perturbations of intracellular transport of proteins. The term includes, but is not limited to, denaturation of proteins, misfolding of
proteins, chelation of protein cofactors, cross-linking of proteins, both oxygen-dependent and -independent oxidation of inter- and intra-chain bonds, such as disulfide bonds, alkylation of proteins, oxidation of individual amino acids and protein damage caused by exposure to heavy metals, such as cadmium and heat.

I use the term "energy/ionic stress" to encompass conditions which affect ATP levels in the cell or ionic gradients across a cell membrane.

Examples of energy stress are forced anaerobic metabolism in the presence of oxygen, perturbations of electron transport, exposure to uncoupling agents, membrane depolarization, osmotic shock, exposure to ions, such as Ca²⁺, exposure to high levels of cAMP and exposure to ethanol.

The term "cell surface receptor-mediated stress" refers to those conditions which alter the transcription level of genes whose expression is regulated by the interaction of a cell surface receptor with a ligand. Examples of such stress include exposure of the skin, eyes or mucous membranes to irritants, allergens or inflammatory compounds.

The term "stress promoter induction" refers to conditions which increase the level of expression of a gene product operably linked to a native stress promoter or a recombinantly derived stress promoter which contains a response element. The term "operative linkage", "operatively linked" or "operably linked" refers to the positioning of the promoter relative to the gene such that transcription of the gene is regulated by the promoter. The term encompasses both recombinant constructs, as well as the structure of a naturally occurring promoter and its associated gene.

The term "determining and characterizing the toxicity of a compound" includes identifying a compound
as a toxin and elucidating its mechanism of action within the cell.

The term "nucleic acid sequences" as used in this application, includes RNA, single or double-stranded cDNA or portions thereof, single or double-stranded genomic DNA or portions thereof, or single or double stranded synthetic oligonucleotides.

Whereas every gene is controlled by a unique promoter, genes which respond to identical stresses contain a common response element within their promoters. Accordingly, the same response element is responsible for inducing expression of a family of genes upon exposure to a certain stress. When isolated and operably linked to a minimal promoter and a structural gene, the resulting construct functions like a stress promoter. This is particularly useful in dissecting a native stress promoter that responds to multiple stresses into its component parts.

Individual cells respond to toxic stimuli, in part, by activating specific genes whose protein products detoxify the stimuli or repair damage caused thereby. Eukaryotic cells have large number of genetic and biochemical responses to damage and stress. At least 50 different mammalian stress genes have already been isolated and characterized. These genes are induced by a variety of chemical and physical stresses or cellular damage.

Among the chemical stresses which induce one or more of these identified genes are exposure of the cell to mercury, heavy metals, nitrooxides, aromatic hydrocarbons, acidity, basicity, alkylating agents, peroxidizing agents, cross-linking agents, ionophores, redox active agents, electrophilic compounds, inflammatory agents, hydrophobic cytotoxic drugs, ethanol, steroids, uncoupling agents, tumor promoters and cellular factors, such as tumor necrosis factor,
growth factors and interferon. Physical stresses include exposure to UV radiation, heat or X-rays.

Examples of cellular damage which induce these identified genes are lipid oxidation, peroxisome proliferation, DNA strand breaks, DNA alkylation, DNA cross-linking, DNA oxidation, osmotic imbalance, protein oxidation, protein misfolding, protein alkylation, ATP depletion, membrane permeabilization, glutathione depletion and alterations in signal transduction. Many more stress genes are believed to exist. The identification and characterization of these additional stress genes is highly desirable in understanding what effects various chemical stresses have on the cell.

The present invention provides diagnostic kits and methods for determining and characterizing the toxicity of a compound in terms of the type of damage it causes within the cell, i.e., DNA damage, protein damage, redox damage, energy damage, ionic damage, etc.

According to one embodiment, each diagnostic kit of this invention comprises a plurality of eukaryotic cells, each of which harbors at least one promoter or one promoter element which responds to stress. The plurality of cells, in toto, must comprise at least one promoter or promoter element which responds to each of the aforementioned types of stresses -- redox, DNA, protein and energy/ionic -- operably linked to a gene encoding a detectable product.

According to one embodiment, the plurality of cells in this kit are actually a single cell line, wherein each cell contains all of the different types of stress promoters and wherein each of those promoters is activated upon exposure to the appropriate stress. In this embodiment, the genes operatively linked to the stress promoters are most preferably the native stress genes. In this manner no genetic manipulation need be
carried out on the cells prior to running an assay. In this preferred embodiment, the kits further comprise oligonucleotides or cDNAs which are complementary to at least a portion of either the coding or non-coding strand of the genes under control of the specific stress promoters. The oligonucleotides are used to detect and quantify the mRNA transcripts of those genes or the cDNA complement thereof, either of which may be the detectable product in this embodiment.

It should be noted that although all eukaryotic cells contain numerous stress promoters within their genomes, some of those promoters may or may not be activatable upon exposure to the proper stress. This is especially true in higher eukaryotes, such as mammals. Those cell lines whose stress promoters do respond to almost all of the appropriate stresses are preferred in the kits of this invention. These include primary tissue from mammalian liver, heart, lung, kidney, brain, or other organ, as well as mammalian derived cell lines established from these tissues available from American Type Culture Collection (ATCC, Rockville, MD). More preferred are HepG2 cells, HeLa cells and WIL-2 cells. Most preferred are HepG2 cells.

The oligonucleotides employed in the above diagnostic kits and methods of this invention are chosen based upon their ability to specifically hybridize under relatively high stringency conditions to the either the transcription product of the gene operatively linked to the various stress promoters or its complement (i.e., a single-stranded cDNA reverse transcribed from that mRNA). The choice of utilizing complementary or homologous oligonucleotides depends upon the method used for detecting the transcription products. These various methods are described later in the application.
Because the DNA sequence of many mammalian stress genes are known, hybridizable oligonucleotides are easily constructed. It should be noted that 100% homology or complementarity between the oligonucleotide and the stress gene mRNA is not required. This is because the oligonucleotide may be designed based upon the sequence of a stress gene from a species different from the source of the cells utilized in the kits and methods of this invention.

While it is expected that similar stress genes from different mammalian species will be closely related, the transcripts from those genes will most likely not have identical nucleotide sequences. Accordingly, the oligonucleotides utilized in the kits and methods of this invention are preferably at least 95% homologous or complementary. Preferably, the oligonucleotides are between 20 and 500 base pairs long. Most preferably, the oligonucleotides are between 50 and 100 base pairs.

More preferably, the oligonucleotides are synthesized using an oligonucleotide synthesizer, optionally followed by polymerase chain reaction ("PCR"). In this procedure, an oligonucleotide having a sequence identical to a portion of either the template strand or the non-coding strand and within the coding region of a known, sequenced stress gene is synthesized. If PCR is to be used to increase the quantity of oligonucleotide, the oligonucleotide is synthesized with an additional 6 to 12 nucleotides at each end. Those extra nucleotides serve as targets for complementary primers in a PCR reaction. Preferably the extra nucleotides at each end are complementary to one another. This allows a single primer to prime off of both the original oligonucleotide and the PCR product thereof. Most preferably, the extra
nucleotides at each end are complementary homohexamers, i.e., AAAAAA at one end and TTTTTT at the other.

During PCR, one or more labeled nucleotides are preferably included in the polymerase reaction. Preferably the label is $^{32}$P, biotin or a fluorescent marker. This results in a labelled product that can be used directly to detect the level of transcription product. The advantage of this mixed oligonucleotide synthesizer/PCR technique is that microgram quantities of labelled oligonucleotide can be produced in a single procedure. The resulting oligonucleotides may optionally be biotinylated following synthesis and purification.

If the oligonucleotide is used to detect cDNA reverse transcripts of the transcription product, it is preferable that they not be labelled. In this embodiment, it is preferred that the label be incorporated into the cDNA, rather than the oligonucleotide.

The design of appropriate oligonucleotide probes for use in the kits and methods of this invention is relatively straightforward. Obviously, they should have high sequence similarity or complementarity to the stress gene mRNA to which they are designed to hybridize. The oligonucleotides in any particular kit should also have approximately the same melting temperature ($T_m$) so that a single warming apparatus (such as a water bath) may be utilized when carrying out hybridization and subsequent washing steps. Preferably the oligonucleotides are designed to have a $T_m$ of greater than 70°C in 0.2X SSC. To determine which portions of the coding regions of the stress gene to use in designing oligonucleotide probes, one may utilize a commercially available computer program, such as OLIGO (National Biosciences, Plymouth, MN).
According to another embodiment, each of the plurality of eukaryotic cells in the diagnostic kit of this invention harbors a stress promoter or a stress response element which is operatively linked to a heterologous gene encoding a detectable product. In this embodiment, it is preferable that the same heterologous gene be linked to the various stress promoters or response elements in the kit. In this manner, only a single assay need be performed to detect induction of any of the stress promoters and stress response elements. It is also preferable that each cell within the kit contains only a single stress promoter or response element/heterologous gene construct. Thus, the expression of the detectable product in any given cell in the kit can be specifically correlated to the induction of a single stress promoter or response element.

The diagnostic kits and methods of this invention employ a plurality of eukaryotic cells, which, in toto, comprise promoters or response elements that respond to each of: redox stress, DNA stress, protein stress and energy stress. The preferred promoters and response elements of this invention for use with mammalian cells are listed below in Table 1.

<table>
<thead>
<tr>
<th>Promoter</th>
<th>Redox</th>
<th>DNA</th>
<th>Protein</th>
<th>Energy/ Ionic</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP1A1</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GST Yα</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GADD45</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GRP78</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>JUN</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>FOS</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
Table 1 (cont’d)

<table>
<thead>
<tr>
<th>Promoter</th>
<th>Redox</th>
<th>DNA</th>
<th>Protein</th>
<th>Energy/Ionic</th>
</tr>
</thead>
<tbody>
<tr>
<td>XHF</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HSP70</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>MT IIa</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GADD153</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ALDH1</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HMO</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRE</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>XRE</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>NFkBRE</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RARE</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ThRE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPRE</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>TRE</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>ERE</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>p53RE</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Preferably, the promoters or response elements which respond to redox stress in the methods and kits of this invention are selected from the promoters of the CYP1A1, GST Ya, JUN, ALDH1 and HMO genes and the XRE, NFkBRE, PPRE, RARE, ERE, and ThRE response elements.

The CYP1A1 gene encodes cytochrome P450 1A1, an enzyme involved in the metabolism of polycyclic aromatic hydrocarbons, such as benzo(a)pyrene. The gene is inducible by aromatic hydrocarbons, plant flavones and also by tetrachlorodibenzo-p-dioxin (TCDD), one of the most potent teratogens and tumor promoters [L. A. Neuhold et al., Mol. Cell. Biol., 9, pp. 2378-2386 (1989); Y. Fujii-Kuriyama et al., The FASEB J., 6, pp. 706-710 (1992); D. W. Nebert et al., Env. Health Perspec., pp. 13-25 (1990); R. A. Dixon et al., Biol. Rev., 61, pp. 239-241 (1986)]. The sequence of this gene is described in K. Sogawa et al., Proc.
Natl. Acad. Sci. USA, pp. 8044-8048 (1986), the
disclosure of which is herein incorporated by
reference.

The GST Ya gene encodes the glutathione S-
transferase Ya subunit, a unique xenobiotic-responsive
element. The redox stress-sensitive portion of the GST
Ya promoter is strongly induced by electrophilic
herbicides, insecticides and planar aromatic
hydrocarbons such as β-naphthoflavone and 3-
Acad. Sci. USA, 87, pp. 3826-3830 (1990)]. The
sequence of this gene is described in T. H. Rushmore et
al., supra, the disclosure of which is herein
incorporated by reference.

The JUN oncogene codes for c-jun which
participates in the formation of the AP-1 complex -- a
transcriptional activator. Redox stresses which
activate the JUN gene are superoxide radicals and UVA
radiation. The sequence of this gene is described in
R. De Groot et al., EMBO J., 10, pp. 2523-2532 (1991),
the disclosure of which is herein incorporated by
reference.

The ALDH 2 gene encodes aldehyde
dehydrogenase and is induced by aldehydes and
peroxisome proliferators [D. W. Nebert, Env. Health
Persp., 88, pp. 13-25 (1990)]. The sequence of that
gene is described in L.C. Hsu et al., Proc. Natl. Acad.
Sci. USA, 82, pp. 3771-3775 (1985), the disclosure of
which is herein incorporated by reference.

The HMO gene codes for heme oxygenase. The
promoter is induced by the following redox stresses:
oxidative stress, hydrogen peroxides, and sodium
Acad. Sci. USA, 86, pp. 99-103 (1989)]. The sequence
of this gene is described in that document, the
disclosure of which is herein incorporated by reference.

The XRE is a redox stress response element. It responds to xenobiotics, such as aromatic hydrocarbons [T. H. Rushmore et al., Proc. Natl. Acad. Sci. USA, 87, pp. 3826-3830 (1990)]. The sequence of this response element is described in that document, the disclosure of which is herein incorporated by reference.


PPRE is the peroxisome proliferation response element. It is a redox stress responsive element that is induced by peroxisome proliferators [C. Dreyer et al., Cell, 68, pp. 879-887 (1992)]. The sequence of this response element is described in that document, the disclosure of which is herein incorporated by reference.

RARE is the retinoic acid response element. It is a redox stress-sensitive response element that responds to the steroid hormone retinoic acid and its analogs [H. de The, et al., Nature, 343, pp. 177-180 (1990), the disclosure of which is herein incorporated by reference].

ERE is the estrogen response element. It responds to redox stress that is induced by estrogenic compounds. The sequence of the ERE is described in V. Kumar, et al., Cell, 55, pp. 145-156 (1988), the
disclosure of which is herein incorporated by reference.

ThRE is the thyroid hormone response element. It responds to redox stress that is induced by thyroid hormone and its analogs. The sequence of the ThRE is described in M. Beato, Cell, 56, pp. 335-344 (1989), the disclosure of which is herein incorporated by reference.

Other promoters and response elements which respond to redox and can be utilized in the kits and methods of this invention may be selected from those listed in Table 2, below. In the brief description of each of these genes and response elements that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets. The disclosure of each of these documents is herein incorporated by reference.


The promoters and response elements which respond to DNA stress that are useful in the methods and kits of this invention are preferably selected from the promoters of the GST Ya, GADD45, JUN, POS, XHF and GADD153 genes and the TRE and p53RE response elements.

The GST Ya gene is described above. Its DNA stress-sensitive component is induced by alkylated DNA.

The GADD45 gene encodes a growth arrest and DNA damage responsive protein. The GADD45 gene is induced by UV irradiation, X-rays, and the DNA damaging agent, methyl methane sulfonate (MMS). This gene is described in Q. Zhan et al., Mol. Cell Biol., 13, pp. 4242-50 (1993), the disclosure of which is incorporated by reference.

The JUN gene has a DNA stress-sensitive component that is induced by UVA radiation, tumor promoters and growth factors.

The POS gene encodes the oncogene c-fos. The DNA stress-sensitive components of its promoter are induced by tumor promoters and growth factors [E. M. Haliday, EMBO J., 10, pp. 109-115 (1991)]. The sequence of this gene is described in F. van Straaten et al., Proc. Natl. Acad. Sci. USA, 80, pp. 3183-3187.
(1983), the disclosure of which is incorporated herein by reference.

The XHF gene codes for collagenase and is activated by mitogenesis, inflammatory agents, UV radiation, and also in response to the tumor promoter, 12-0-tetradecanoyl-phorbol-13-acetate (TPA). The sequence of this gene is described in P. Angel et al., Mol. Cell. Biol., 7, pp. 2256-2266 (1987), the disclosure of which is herein incorporated by reference.


TRE is the TPA response element. It responds to DNA stress induced by phorbol esters. The sequence of TRE is described in P. Angel et al., Cell, 55, pp. 875-85 (1988), the disclosure of which is herein incorporated by reference.

p53RE in the p53 response element. It is responsive to DNA stress and is induced by X-rays and MMS. The sequence of the p53RE is described in Q. Zahn, et al., Mol. Cell. Biol., 13, pp. 4242-4250 (1993), the disclosure of which is herein incorporated by reference.

Other promoters which respond to DNA stress and are useful in the methods and kits of this invention are listed in Table 2, below. In the brief description of each of these gene that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets. The disclosure of each of these documents is herein incorporated by reference.
Proc. Natl. Acad. Sci. USA, 85, pp. 7177-81 (1988)). PPa, which was also discussed above, responds to DNA stress caused by DNA damage. DRA encodes HLA class II and is induced by interferon gamma [A. J. Korman et al., Proc. Natl. Acad. Sci. USA, 79, pp. 6013-17 (1982); D. A. Shackelford et al., Immunol. Rev., 66, pp. 133- (1982)]. The MnSOD promoter, which is described above, also contains a DNA stress-responsive element that is induced by tumor necrosis factor. The MDR-1 gene encodes a protein which imparts multi-drug resistance and is mainly induced by hydrophobic cytotoxic drugs [J. A. Silverman et al., Gene, 106, pp. 229-236 (1991)]. The beta-pol gene encodes the DNA repair enzyme DNA polymerase beta and responds to N-methyl-N'-nitro-N-nitrosoguanidine (MNGN), mechlorethamine hydrochloride (HN2), and cis-platinum(II) diamine dichloride (cis-Pt) [S. G. Widen, et al., J. Biol. Chem., 263, pp. 16992-98 (1988)]. The stromelysin-1 gene encodes a protein that is induced by phorbol esters, such as PMA [K. L. Sirum et al., Biochemistry, 28, pp. 8691-98 (1989)]. The PCNA gene encodes proliferating cell nuclear antigen which is induced by tumor promoters [S. Travali et al., J. Biol. Chem., 264, pp. 7466-72 (1989)].

Promoters which respond to protein stress useful in the methods and kits of this invention are preferably selected from GRP78, JUN, FOS, HSP70 and MTIIA.

JUN and FOS, which are described above, both contain protein stress-responsive elements that are induced by heat.


MT IIA, which encodes metallothioneine IIA, is induced by heavy metals and glucocorticoids [M. Karin et al., Nature, 299, pp. 797-802 (1982)]. The sequence of that gene is described in the above reference, the disclosure of which is herein incorporated by reference.

Other promoters which may be employed in the kits and methods of this invention to detect protein stress may be selected from those promoters listed in Table 2, below, which respond to protein stress. In the brief description of each of these gene that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets. The disclosure of each of these documents is herein incorporated by reference.


The preferred promoters and response elements which respond to energy/ionic stress in the methods and
kits of this invention are the promoters of the FOS and GRP78 genes and the CRE response element.

FOS, which is described above, contains the cAMP response element ("CRE") [W. J. Roesler et al., J. Biol. Chem., 263, pp. 9063-9066 (1988)].

GRP78, which is also described above, contains an energy/ionic stress responsive element that responds to calcium ionophores.

CRE is the cAMP response element. It is an energy/ionic stress-sensitive response element which responds to increased levels of cAMP [J. Roesler et al., J. Biol. Chem., 263, pp. 9063-66 (1988), the disclosure of which is herein incorporated by reference.]

Other energy/ionic stress promoters that may be employed in the kits and methods of this invention are listed in Table 2, below. In the brief description of each of these gene that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets. The disclosure of each of these documents is herein incorporated by reference.

Two cytochrome P450 genes -- CYF11B2 which is induced by cAMP; and CYP2E1, which is induced by ethanol -- contain energy/ionic stress responsive elements. 2'-5' AS contains an element which responds to energy/ionic stress induced by ethanol. DBH, which encodes dopamine β-hydroxylase [B. Grima, Nature, 326, pp. 707-11 (1987)] and TH, which encodes tyrosine hydroxylase [A. Lamouroux et al., EMBO J., 6, pp. 3921-37 (1987)] are both induced by membrane depolarization. CDC, which encodes ornithine decarboxylase, is induced by osmotic shock [N. J. Hickok et al., DNA, 6, pp. 179-87 (1987)]. G6PD encodes glucose-6-phosphate dehydrogenase and is induced by ATP depletion. PKC contains an energy/ionic stress-responsive element which is induced by Na/K ATPase depletion. PVALB
encodes parvalbumin and is induced by calcium ions [C. Lutum et al. GenBank Accession number X63070]. Stromelysin-1 contains an energy/ionic stress-responsive element which is induced by calcium ionophores.

### TABLE 2

**Other Mammalian Stress Promoters**

<table>
<thead>
<tr>
<th>Promoter</th>
<th>Redox</th>
<th>DNA</th>
<th>Protein</th>
<th>Energy/ Ionic</th>
</tr>
</thead>
<tbody>
<tr>
<td>UGT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP11B2</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Cu.ZnSOD</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MnSOD</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NMO 1</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALDH 2</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADPRT</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>GP</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAS 2.3</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGR-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGMT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNA Pol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>beta-pol</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCNA</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PGHS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOX</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISG15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DRA</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDR-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2'5'-AS</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>FAOxase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PBE</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPAR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MT 1A/III</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>TH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DBH</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>ODC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eh</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>CYP2B2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 2 (cont’d)

<table>
<thead>
<tr>
<th>Promoter</th>
<th>Redox</th>
<th>DNA</th>
<th>Protein</th>
<th>Energy/ Ionic</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP2E1</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>CYP3A4</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P450b</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>P450d</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TPO1/TPO2</td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPa</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>G3PD</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>PKC</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>PVALB</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Stromelysin-1</td>
<td></td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>GST2</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GAPDH</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NQO</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCNA</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ARE</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Because response elements can only be isolated from the promoters which contain them by recombinant DNA methods, the use of such elements in the kits and methods of this invention is limited to embodiments utilizing promoter-heterologous gene constructs.

In order to operatively link a response element to a heterologous gene, it must first be ligated to a minimal promoter. A minimal promoter is one which constitutively causes a basal expression of a gene operatively linked thereto. Preferred minimal promoters are the SV40 minimal promoter, the TK minimal promoter or the β-interferon minimal promoter. These minimal promoters are well known in the art. This minimal promoter/response element construct is then operatively linked to the heterologous gene by well-known recombinant DNA methods.

Many of the above described promoters, or functional equivalents thereof, are present in other
eukaryotes, such as nematodes, yeast, insects, reptiles, amphibians and plants.


The appropriate combination of any or all of these promoters, as well as other known yeast stress promoters, may be utilized in the methods and kits of this invention. It will be understood that if yeast stress promoters are employed, yeast hosts are preferred and should be grown under conditions appropriate for such a host. Such conditions are well known in the art.

The most preferred kits and methods which utilize oligonucleotides to detect toxicity comprise the following stress promoters: ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN and MTIIA. The most preferred kits and methods which utilize reporter gene expression to detect toxicity comprise the following stress promoters and response elements: CYP1A1, GST Ya, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE and p53RE.

According to another embodiment of this invention, the diagnostic kits and methods additionally employ at least one cell surface receptor-mediated stress promoter. Such kits and methods are particularly useful for determining and characterizing
the toxicity of a compound on external organs, such as skin, the eye or mucous membranes. The use of cell surface receptor-mediated stress promoters allows for the detection of compounds which can cause local irritation or inflammation of such external organs.

Irritants and inflammatory agents may cause sub-lethal cell injury that cannot be detected histologically. Such toxins would not be toxic to an animal as a whole in a classic sense and thus may escape detection by methods such as live animal testing. The use of cell surface receptor-mediated stress promoters in the kits and methods of this invention allow for the detection and characterization of such local irritants or inflammatory agents, as well as the ability to distinguish between the two on a subcellular level -- something that whole animal testing cannot achieve.

The preferred cell surface receptor-mediated stress promoters for use in such kits are selected from the promoters of the IL-1 alpha, G-CSF, GM-CSF, TNF-alpha, IL-3, IL-6, IL-8, ICAM-1 and stromelysin-1 genes.

The Interleukin (IL)-1 alpha gene encodes a cytokine that is induced by mitogens, lipopolysaccharide (LPS), PMA, silica, other cytokines, and UVB irradiation [T. A. Luger et al., J. Invest. Dermatol., 95, pp. 100S-104S (1990)]. The sequence of that gene is described in Y. Furutani et al., Nucleic Acids Res., 14, pp. 3167-79 (1986), and the disclosure of which is herein incorporated by reference.

The granulocyte colony stimulating factor (G-CSF) gene produces a protein that is induced by endotoxin, interferons, and PMA [T. A. Luger et al., J. Invest. Dermatol., 95, pp. 100S-104S (1990)]. The sequence of this gene is described in S. Nagata et al.,
EMBO J., 5, pp. 575-581 (1986), the disclosure of which is herein incorporated by reference.

The granulocyte macrophage colony stimulating factor (GM-CSF) gene encodes a protein that is produced in response to the same stimuli as G-CSF (T. A. Luger et al., supra). The sequence of this gene is described in S. Miyatake et al., EMBO J., 4, pp. 2561-2568 (1985), the disclosure of which is herein incorporated by reference.


The IL-3 gene encodes a product of the same name and is induced by interferon (IFN) gamma, PMA, and UVB irradiation [T. A. Luger et al., supra]. The sequence of that gene is described in D. R. Cohen et al., Nucl. Acids Res., 14, pp. 3641-58 (1986), the disclosure of which is herein incorporated by reference.

The IL-6 gene produces a protein that is expressed in response to other cytokines, bacterial toxins, viruses, tumor promoters and sodium lauryl sulphate [T. Hunziker et al., Brit. J. Dermatol., 127, pp. 254-57 (1992) and T. A. Luger et al., J. Invest. Dermatol., 95, 100S-104S (1990)]. The sequence of this gene is described in K. Yasukawa et al., EMBO J., 6, pp. 2939-45 (1987), the disclosure of which is herein incorporated by reference.

The IL-8 gene is induced by the cytokines IL-1 alpha, tumor necrosis factor (TNF-alpha), and IFN-gamma, as well as by LPS, and tumor promoters [I. C. Oliveira et al., Proc. Natl. Acad. Sci. USA, 89, pp.
9049-53 (1992)]. The sequence of that gene is described in N. Mukaida et al., J. Immunol., 143, pp. 1366-71 (1989), the disclosure of which is herein incorporated by reference.

The intracellular adhesion molecule (ICAM)-1 gene encodes a protein that is induced by cytokines, LPS, hydrocortisone, and PMA [S. W. Caughman et al., J. Invest. Dermatol., 98, pp. 61S-65S (1992)]. The sequence of this gene is described in B. G. Stade et al., Immunobiology, 181, pp. 851-56 (1990), the disclosure of which is herein incorporated by reference.

The stromelysin-1 gene contains a cell surfaced receptor-mediated stress element that is induced by epidermal growth factor.

Other cell surface receptor-mediated stress promoters that may be utilized in the kits and methods of this invention include the promoters of IL-1 beta, TGF-alpha, IL-10 and M-CSF genes, as well as the promoters of the genes that encode the cell surface receptor that regulates the expression of any of the above genes. In the brief description of each of these genes that follows, the document which discloses the DNA sequence of the particular gene is indicated in brackets. The disclosure of each of these documents is herein incorporated by reference.

The IL-1 beta gene is induced by the same agents as IL-1 alpha [J. J. Huang et al., J. Immunol., 140, pp. 3838-43 (1988)]. The transforming growth factor (TGF) alpha gene encodes a protein that is induced by itself as well as by IFN-gamma [F. Iris et al., Nature Genetics, 3, pp. 137-45 (1993)]. IL-10 is induced by contact allergens such as trinitrochlorobenzene (TNCB) and haptens [J. M. Kim et al., J. Immunol., 148, pp. 3618-23 (1992)]. The other
cell surface receptor-mediated stress genes have also been described in the art.

The diagnostic kits and methods of this invention rely on the induction of specific stress promoters or stress response elements and the transcription and/or translation of a gene operatively linked thereto.

For embodiments of the invention that employ a heterologous gene operatively linked to a mammalian stress promoter or stress responsive element, the choice of gene is essentially limitless. The only parameters that are required are (1) that a DNA sequence encoding the assayable product has been characterized; and (2) that the product of the gene can be detected. Sufficient characterization includes knowledge of the entire coding sequence, availability of a genomic clone or knowledge of a sufficient number of restriction sites within the genomic DNA sequence to allow the gene to be manipulated so as to create an operative linkage to the stress promoter.

Promoters of most mammalian stress genes are inducible by more than one type of stress. This is because such promoters contain within their sequence a number of stress response elements, each of which is responsive to a different type of stress. In embodiments that utilize such multiple stress promoters it is preferable that another promoter which responds to only one of the multiple stresses also be employed. This is true whether native promoter-gene systems or recombinant promoter-assayable gene fusions are used. For example, the HMO promoter and the JUN promoter are induced by both peroxides and by UVA rays. Thus, these promoters respond to both redox stress and DNA stress. An NMO1 promoter, which responds solely to oxidative stress, may be used together with an HMO or JUN promoter. This combination of promoters allows one to
determine whether induction of the multiple stress promoter was due to redox stress or UVA light. In this manner, the nature of the stress caused by a compound can be more accurately determined.

According to another embodiment of this invention, individual response elements of a promoter may be isolated and then operatively linked to a mammalian minimal promoter and to a gene which encodes a detectable product. Thus, expression of the detectable product in the presence of a compound is correlated with only one particular type of stress.

In embodiments which employ a gene encoding a detectable product, the assayable product is preferably β-galactosidase (encoded by the lacZ gene), chloramphenicol acetyl transferase (encoded by the CAT gene), galactose kinase (encoded by the galK gene), β-glucosidase (encoded by the gus gene), glutathione transferase, human growth hormone (encoded by the hGH gene) or firefly luciferase (encoded by the lux gene).

Most preferably, the CAT gene is employed.

The stress promoter-assayable product fusions harbored by the hosts employed in certain of the diagnostic kits and methods of this invention may be made using standard recombinant DNA techniques that are well known in the art. The choice of techniques depends upon what is known about the particular stress promoter to be used in the strain.

If a genomic fragment containing a stress promoter and its gene have been isolated or cloned into a vector, the promoter is removed by appropriate restriction enzyme digests. The promoter fragment is then isolated and operably linked to a gene encoding an assayable product in a plasmid. The vector should also contain a marker, such as Neo, for identifying stable transfectants. Screening for a functional fusion is achieved by exposing transfectants to a stress which is
known to induce the specific stress promoter and assaying for the detectable gene product.

If the nucleotide sequence of the stress promoter and its gene is known, polymerase chain reaction technology may be employed to produce assayable protein fusions. Specifically, one synthesizes primers which are complementary to the 5' and 3' ends of the stress promoter portion of the gene, hybridizes those primers to denatured, total mammalian DNA under appropriate conditions and performs PCR. In this manner, clonable quantities of any sequenced stress promoter may be obtained. Once the stress promoter DNA has been obtained, it is operatively linked to a DNA encoding an assayable protein in an appropriate vector, as described above. Such methods are well-known in the art.

Constructing operable fusions of stress promoter response elements to a gene encoding a detectable product is also carried out by standard recombinant DNA techniques. Because response elements are small, DNA encoding them may be produced using an oligonucleotide synthesizer. Oligonucleotides corresponding to both strands of the response element are synthesized, annealed together and cloned into a plasmid containing a reporter gene under control of a minimal promoter. Alternatively, the double stranded oligonucleotides can be allowed to multimerize via self ligation prior to insertion into a vector. The multiple copies of the response element allow for higher expression of the detectable product upon stress induction.

Embodiments of the present invention that employ native stress genes as the genes encoding an assayable product require no genetic manipulation prior to assaying toxicity.
The choice of cell line to use in the kits and methods of this invention is dependent upon the assay to be used to determine toxicity. For those embodiments which utilize stress promoter-assayable product gene fusions, the cells must be able to produce the expression product in assayable form. Moreover, those cells should not constitutively produce the assayable product from another copy of the gene in their genome.

For embodiments which utilize the cell's native stress genes, the choice of cells is based upon the ability of those genes to be induced by stress. Preferred cells for embodiments that do not employ cell surface receptor-mediated stress promoters are HeLa, HepG2 and WIL-2. For those kits and methods that do employ cell surface receptor-mediated stress promoters, the preferred cell line is one derived from the organ of concern. For example, if the stress kits and methods are intended to identify compounds which affect the skin, a skin fibroblast or keratinocyte cell line, such as SCC12 or its derivatives, such as C6C1, is preferred. For kits and methods seeking to identify toxins to the eye, a corneal cell line is most preferred.

When utilizing stress promoter-assayable product fusions, it is preferable that each host employed in the kits and methods of this invention harbors only one such fusion. In this manner, if a compound induces expression of the assayable gene product in any particular host cell, the specific type of stress caused by the compound can unambiguously be identified.

It is known that some compounds are not toxic to mammals in their native form, but become toxic after being processed by the liver. Therefore, according to another embodiment of this invention, the compound to
be tested in the methods and kits of this invention is pre-treated with an S9 liver extract. Methods for preparing an S9 liver extract ("S9") are described by S. Vennitt et al., in *Mutagenicity Testing - A Practical Approach*, S. Vennitt et al., eds., IRL Press, Oxford, England, pp. 52-57 (1984), the disclosure of which is herein incorporated by reference. S9 is generally a crude homogenate of rat liver with insoluble particles removed by low speed centrifugation, but may also be prepared from human or other mammalian liver. S9 is incubated with the test compound in a potassium buffer containing NAD(P)H to mimic stage I and stage II biotransformation of compounds normally performed by the mammalian liver prior to performing the toxicity assay. If, however, primary mammalian liver cells are utilized in the kits and methods of this invention, S9 pre-treatment is unnecessary. The cells will be capable of performing stage I and II biotransformation of compounds under assay growth conditions.

Alternatively, the cells utilized in the kits and methods of this invention are co-cultured with cells capable of performing stage I and II biotransformation, preferably, a primary liver cell line. The biotransformation of the compound being assayed is, in this instance, performed by those other cells, rather than enzymatic fractions derived from liver cells.

Prior to carrying out an assay on a compound of unknown toxicity using the methods and kits of this invention, standard curves should be generated utilizing at least one and preferably at least three compounds that are known to induce each specific stress promoter or response element that will be used to screen the unknown compound.
Each known chemical should more preferably be tested against all of the promoters, not just the promoter that it is known to induce. And each chemical should be assayed over a sufficiently wide range of concentrations to provide a useful standard curve, preferably 1 picomolar to 1 millimolar as well as at several time points.

Once the standard curves have been generated, a computer database containing those curves is generated. This database is then used to compare stress promoter-induction profiles of the compounds to be tested with those of the known toxins used to generate the standard curve. Thus, the results for any untested compound are expressed in terms of relative toxicity compared to known inducers of stress promoters.

Each of the characterization and toxicity determination methods of this invention comprise the first step of culturing the cells both prior to and following exposure to a potential toxic compound. Culture conditions will vary depending upon the cell type utilized. Most preferably, immortalized human liver cells (HepG2) are used. Growth of these cells is performed under standard tissue culture conditions -- minimal essential medium at 37°C, 5% CO₂. The cells are routinely grown in 165 cm² flasks until they reach a density of about 5 x 10⁶ cells/ml.

Following this initial growth, the cells are subcultured and exposed to the compound to be tested. A typical assay employs approximately 2.75 x 10⁵ cells/ml. For initial tests on a compound, a series of 10-fold dilutions of the compound should be used. Another series of dilutions of the compound which have been pre-incubated with S9 fraction should also be prepared and added to a second portion of each culture. A third portion of each culture, which serves as a
control, is not exposed to the compound, but otherwise treated in the same manner as described below.

All of the cultures are then allowed to incubate at normal growth temperature for a period of time ranging from 5 minutes to 48 hours. More preferably, exposure to the toxic or test compound is for about 2 to 32 hours. Following exposure to the test compound, the level of assayable product or stress gene mRNAs are measured.

If the embodiment measuring assayable product is employed, quantification may be carried out in a number of ways that are well known in the art. For example, a colorimetric substrate may be utilized if the expression product is an enzyme. Appropriate colorimetric substrates for specific enzymes are well-known in the art. Alternatively, an assay which employs specific antibodies, such as an RIA or ELISA, can be used to detect the expression product.

Depending upon the nature of the assay used, the buffer conditions of the lysed culture or supernatant may need to be adjusted. Accordingly, suitable buffer may be added to the lysed culture or supernatant so that optimal conditions for the particular assay are obtained. For example, if the assayable product is to be detected by an RIA or ELISA assay, the buffer conditions must be adjusted to a neutral pH to allow for maximal antibody-antigen complex formation and to minimize non-specific antibody binding. Such conditions are well known in the art and are exemplified by a final buffer condition of 50 mM phosphate buffer, 150 mM NaCl, pH 7.0. If the assayable product is an enzyme and detection is to be achieved by a colorimetric substrate assay, buffer conditions must be optimized for maximal enzymatic activity and minimal non-catalytic cleavage of the
substrate. These conditions are conventional and vary depending on the enzyme to be assayed.

In the most preferred embodiment of this aspect of the invention, the detectable product is chloramphenicol acetyl transferase (CAT). Assays for this enzyme are well-known in the art and are described in J. Sambrook et al., "Molecular Cloning - A Laboratory Manual, Second Edition", Cold Spring Harbor Laboratory Press, pp. 16.60-16.65 (1989), the disclosure of which is herein incorporated by reference. That reference also describes assays for β-galactosidase, another assayable product useful in the methods and kits of this invention (pp. 16.66-16.67).

In embodiments that utilize transcription level to determine stress gene induction, the level of mRNA transcribed from genes operatively linked to the stress promoters utilized in the kits and methods of this invention must be measured ("stress gene mRNA"). This requires that total RNA or mRNA be isolated from exposed cells. This may be achieved by any of the numerous and well-known methodologies. Commercially available mRNA or total RNA isolation kits may also be utilized, such as is available from Stratagene (La Jolla, CA). Preferably the cells are lysed with guanidinium isothiocyanate (GTC). The lysate is then acidified with sodium acetate buffer (pH 5.2) and the contaminants extracted with phenol. The RNA is then twice precipitated with ethanol, dried and redissolved in water.

Once the RNA has been isolated, the level of stress gene mRNA can be measured in a number of ways, either directly or indirectly. In the direct method, oligonucleotides that are complementary to stress gene mRNA are used. In this method, the mRNA isolated from the cells is applied to nitrocellulose paper or nylon membrane filter in a slot blot apparatus. After
diluting the RNA in the apparatus with appropriate salt solution (preferably two volume of 20X SSC) and washing the slots, the nitrocellulose paper or filter is either baked at 80°C for 2 hours in a vacuum oven or UV crosslinked to fix the RNA. The RNA fixed to the nitrocellulose is then hybridized to labeled oligonucleotide probes which are complementary to stress gene mRNAs under appropriate buffer and temperature conditions.

An indirect method utilizes oligonucleotides that are homologous to stress gene mRNAs for detection. This method measures transcription by using the stress gene mRNAs as templates for making labelled single stranded cDNA using reverse transcription. These cDNAs are then detected and quantitated by hybridizing to complementary oligonucleotides (or denatured double-stranded cDNAs) that are bound to a solid support. Preferably, the solid support is a negatively charged membrane and the oligonucleotides are modified by the addition of a positively charged amidite or amino group on the 3' end prior to binding to the membrane. This 3' modification allows the oligonucleotide to bind to the membrane only via its 3' end, allowing for more efficient hybridization than other methods of binding DNA to a solid support.

In either method, a control representing a constitutively expressed "housekeeping gene", such as β-globin, β-tubulin, β-actin or γ-actin, which is not induced by the specific experimental sample, is also used. This provides a control for proper growth and functioning of the cells, as well as the background standard upon which to calculate the amount of specific induction. Following hybridization, the amount of hybridization is quantified. Quantification is achieved by a method that is consistent with the label on the oligonucleotide or cDNA. If a radioisotope is
used as a label, exposure of the membrane to X-ray film followed by densitometry tracing or liquid scintillation counting would be the preferred methods of quantification. If a fluorescent label is used, a fluorometer is used for quantification. In this manner the level of various stress gene inductions can be measured. If a biotinylated label is used, quantification is achieved by using streptavidin conjugated to an enzyme that can yield a measurable colorimetric product.

It is known that while individual compounds may not be toxic, combinations of non-toxic compounds may, in fact be toxic. Therefore, it should be understood that the kits and methods of this invention can also be utilized to determine the potential toxicity of combinations of known and unknown compounds (e.g. drug interactions) in an identical manner to that described above.

This invention also provides stress-specific diagnostic kits and methods. For example, the invention provides redox stress kits and methods; DNA stress kits and methods; protein stress kits and methods; energy/ionic stress kits and methods; and receptor-mediated stress kits and methods. The choice of promoters to use in these stress-specific kits may be made from any of the appropriate promoters described or listed in Tables 1 and 2, above. Preferably these kits employ at least 3, and more preferably at least 8, promoters which respond to different subsets of stresses within the larger group. Most preferably, these specific kits and methods employ at least 12 promoters in those tables which respond to the appropriate stress. These kits and methods allow a more precise and specific analysis of the stresses caused by a compound.
According to another embodiment, the invention provides a method of identifying an antitoxin to a compound determined to be toxic by the methods of this invention. As described above, once a stress promoter induction profile is generated for an unknown compound, that profile is compared to profiles of known compounds in a database. A potential antitoxin to the unknown compound is a known antidote to a compound having a similar stress promoter induction profile. In order to test the efficacy of such an antitoxin, the stress promoter assay is repeated using only those hosts containing stress promoters which were induced by the unknown compound. Each of those hosts is pre-incubated with varying concentrations of the proposed antitoxin prior to the addition of an inducing concentration of unknown compound. If pre-incubation with the proposed antitoxin decreases or obliterates the effect of the unknown compound, such an antitoxin will likely be effective.

Finally, this invention provides a method of improving active drug design. According to this embodiment, a new drug is first tested with any of the above-described kits and methods and its toxicity is determined. The information provided by such methods and kits indicates the cellular mechanism of the drug's toxicity. The portion of the drug that is likely to cause the particular cellular damage indicated may then be appropriately modified or eliminated depending upon the role that portion plays in the drug's pharmaceutical activity. The resulting modified drug is then retested with the kits and methods of this invention to determine if its toxicity has been sufficiently reduced or eliminated. Drugs improved and modified by this method are also within the scope of this invention.
In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

Certain of the basic molecular biology techniques described below are not set forth in detail. Such techniques are well known in the art and are described in the disclosure of Molecular Cloning - A Laboratory Manual Second Edition, J. Sambrook et al., eds., Cold Spring Harbor Laboratory Press, New York (1989), the disclosure of which is herein incorporated by reference.

EXAMPLE 1

Design And Synthesis Of Stress Gene-Specific Oligonucleotide Probes

The nucleotide sequence of each of the stress genes described herein is known. Accordingly, design of specific oligonucleotides is simply a matter of choosing what portion of the gene to model upon. The computer program OLIGO allows one to enter the nucleotide sequence of the gene of interest and analyze the sequence to determine position, length, and composition of oligonucleotides which will hybridize to the sequence of interest at salt concentrations and temperatures selected by the user. Using this program, I have designed the following stress gene-specific complementary oligonucleotides for use in the kits and methods of this invention:

GADD 153 gene: [SEQ ID NO. 1] 5’-AAAAAAACCCAGTCCAACTA CAGACATGGCAGCTGAGTCCCTGCCATTCACCTTGAGAGCTGATTGTCTTTTTT-3’;

XHF1 gene: [SEQ ID NO. 2] 5’-AAAAAGCCAGTATGCACAGC TTTCCACTGCTGCTGCTGTCTTCTGGGGTGGTGTCTTTTTT-3’;
JUN gene:  [SEQ ID NO. 3] 5'-AAAAAACCCCAAGATCCT
GAAACAGAGCATCAGGCCCTGACCAGCCTCCTTTTTT-3';
MnSOD gene:  [SEQ ID NO. 4] 5'-AAAAAAACAACCTGAAC
GTCAACGGAGGAAGTACCAAGGAGCCCTGAGGATTTTTT-3';
HMO gene:  [SEQ ID NO. 5] 5'-AAAAATAAGGCGTCCGC
ACCCGACAGCATGCCAGGATTTTGCAGGGCCCCTTTTT-3';
GST Ya gene:  [SEQ ID NO. 6] 5'-AAAAAAAAAATGTTGGAGCTG
AGTGGGAAAGAACCGAGACTCTCAGTTAATGGTAGCAGTCTTTTTT-3';
HSP70 gene:  [SEQ ID NO. 7] 5'-AAAAAAAGCCGCGCACGTCG
GCATCGACCTGGCACCACCATCCTCTCGGCCTGTTGTTTCATTTTTTT-3';
MDR-1 gene:  [SEQ ID NO. 8] 5'-AAAAAAATACAGCAGAACCTGGAGACCCAACTTATCTCACTTTTT-3';
CYP 1A1 gene:  [SEQ ID NO. 9] 5'-AAAAAAATATCAGGGAAGC
GTTGGGTAGTTAGCAGGAAGATAGGAGTCAGTTTTTTT-3';
FOS gene:  [SEQ ID NO. 10] 5'-AAAAAAATTGCGTGGAGAGG
AGTCTGCGGTTGAGTGGTAGAGGAAGCTATCCCTTTTTTT-3';
NM23 gene:  [SEQ ID NO. 11] 5'-AAAAAAAGGAATCTCATTT
CTAGCCTTTGTACCGTTGCTGTTTGAGGATCTCTCTTTTTTT-3';
ALDH2 gene:  [SEQ ID NO. 12] 5'-AAAAAACNTCTTTGCTTTCC
CGTGTGATGATGCGAGGATCTTCTTTAAACTGAGTTTTTTTT-3';
DRA gene:  [SEQ ID NO. 13] 5'-AAAAAAACAGGTCTAGTCA
CGTGGCTCGAAATGGGAACCTGCACCAAGGTTTTTT-3';
MGMT gene:  [SEQ ID NO. 14] 5'-AAAAAAAGGATTGATGAAATG
AAACGCACCCACTGGACAGCCCGTTGGGAAAGCTGAGCCTCTTTTTT-3';
2'-5' AS gene:  [SEQ ID NO. 15] 5'-AAAAATCTCTACTTTTG
GGTACGCTGCTGCTGACTGCGGATGAGCTCTCTTTTTG-3';
DHFR gene:  [SEQ ID NO. 16] 5'-AAAAAAGCCTGTGACATGCTCCT
GTCACAAAATGTGTAAAGATGGCCTGTTGATCTTTTTTTT-3';
Cu.ZnSOD gene:  [SEQ ID NO. 17] 5'-AAAAAAACACGCACCCCTCT
CCGCGACTACTTTTATGGGACAGACCTTTTTT-3';
ALDH1a gene:  [SEQ ID NO. 18] 5'-AAAAAAGGATGTGCTCCTCC
CAGTTCTTCTCCATTTGCCAGACATCCTGAAATCCCACTTTTTTT-3';
TK gene:  [SEQ ID NO. 19] 5'-AAAAAAAGGATGTGCTCCTCC
ATACTTGATCACGCAGCCATTTTGACTGAGCAATCTGTTTTTTTTT-3';
PVALB gene:  [SEQ ID NO. 20] 5'-AAAAAAACACCTCTC
TCACTCATCCGCACCTTTTTTCTCAGGGCCGACCATTATTTTT-3';
TH gene: [SEQ ID NO. 21] 5’-AAAAAAGACTCTCAGACAC
GAAGTACGTACTTGTGCTTCTGGTCTTGGTAGGTTTTTTT-3’
EH gene: [SEQ ID NO. 22] 5’-AAAAATCTGAAATATAGG
CAGCCAGCACCAGGAGATCGACTCCAGACAGCCCTTTTTT-3’
5
TOP1 gene: [SEQ ID NO. 23] 5’-AAAAAGATAGCGCTCTCTCTTC
CCACCAGGCTACTTCTGTTCTCTCTCTCTCTCTCTCTCTT-3’
TOP2 gene: [SEQ ID NO. 24] 5’-AAAAAGCTCTGCCAGTTTTTCTT
CAGTCATCTTCACAAATATCAAGGCTTGTGGTTTT-3’
MT 1A gene: [SEQ ID NO. 25] 5’-AAAAATCTCTTCTCTTGCGAG
10 GTGGCTCTGCACTTGCACTTGCTCTGCAATGCAAAAGAGGTTTTTTT-3’

The synthesis of the above oligonucleotides was carried out as follows. The specific oligonucleotide was synthesized using an automated oligonucleotide synthesizer [Model 392, Applied Biosystems, Foster City, CA].

I have also designed the following oligonucleotides which are homologous to the indicated stress gene mRNAs, based on the reported nucleotide sequence of the various genes or cDNAs thereof:

ALDH1 gene: [SEQ ID NO. 26] 5’-AATTGCTATGGGCAGGTAAGTG
CCGAGTGGCCCTTTTGCGGATTCAGAT-3’
CYP1A1 gene: [SEQ ID NO. 27] 5’-ATCTGAAGTTCTACCTGAACGGTG
TTTCCACCCCTGATGGCTCTATGCACA-3’
FOS gene: [SEQ ID NO. 28] 5’-GTACTCCAGCTGCACTGCT
25 TACAGCTCTTCTCTGCTCTACCT-3’
GADD153 gene: [SEQ ID NO. 29] 5’-AGGAGAATGAAAGGAAAGGTGGC
ACAGCTAGCTGAGAAGAATGAAAGGCTC-3’
GADD45 gene: [SEQ ID NO. 30] 5’-AGTGCTACATGGATCAATGGGT
TCCAGTGATTAATCTCCCTGAAGGCTG-3’
30 GAPDH gene: [SEQ ID NO. 31] 5’-GTGGTGGACCTGACCTGCGTCT
AGAAAAACCTGCCATAATGATGACAT-3’
GST2 gene: [SEQ ID NO. 32] 5’-CAGCCCCAGAGGAGGCTCCCATGG
ATGAGAAATCTTTTAGAGAGACAGAAGGA-3’
HMO gene: [SEQ ID NO. 33] 5’-CTTACACTCGCTTTCTGTTGCGG
35 ACAGTTGCTACTGGGCTTTA-3’
HSP70 gene: [SEQ ID NO. 34] 5’-AGAAGGACGAGTTTGAGCCACAAG
AGGAAGGAGCTGGAGCCAGGTTGT-3’
JUN gene: [SEQ ID NO. 35] 5’-GCTCAGGGAGCTGAGTCGCCAGGC
TTAAACAGAAATGCTGATGACCCAGCTTA-3’

MDR1 gene: [SEQ ID NO. 36] 5’-GAAAGGCACTCTATTTTTTCAATGTT
CAGTGTCCAGGCTGGGAAAGACGCGG-3’
MT1A gene: [SEQ ID NO. 37] 5’-GCACTGCTCTCTGCCAATGCAAGA
GAGTGCAATGCAACTCTGCTGAGAAG-3’
MTIIA gene: [SEQ ID NO. 38] 5’-CCCGGGCTGATCGCCTGCGGAG

GGCGTCCGGCAAGA-3’

NMO gene: [SEQ ID NO. 39] 5’-ACCACTGATTTTGTGCTCCAAGCGC
CCTTTGACTAAATCTCCAGGGG-3’
PCNA gene: [SEQ ID NO. 40] 5’-ACAAAGCCACTCCACCTCTCTGCA
ACCGTGACACTCAGTTATGTCTGAGACA-3’

NQO gene: [SEQ ID NO. 41] 5’-TTGCTCTCAGCAGATCCTCACAAT
AGCTGACGCTGGCTGTTTTCAGTTTGA-3’

I also designed the following control
oligonucleotides which are homologous to housekeeping
gene transcripts:

ACTG (gamma-actin) gene: [SEQ ID NO. 42] 5’-ACCTTCCAGCA
GATGCTGATTAGCAAGCAGTAGTGCGAGGATCG-3’
BTUB (beta-tubulin) gene: [SEQ ID NO. 43] 5’-TTGAGTGG
ATCCCCAACATGTTGAAAACGGCAGTGCTCAGACTCCCACCT-3’.

These oligonucleotides were each modified at
their 3’ end by the addition of an amino group so that
they could bind to a negatively charged membrane only
via their 3’ end. Such oligonucleotides were
synthesized to order by Operon Technologies, Inc.,
Alameda, CA.

Complementary and homologous oligonucleotide
probes for any of the other stress gene mRNAs that may
be employed in this invention may be similarly designed
using the software described above.
Toxicity Assay Of An Unknown Compound Using Radiolabelled Oligonucleotide Probes

I. Direct Quantification of Stress Gene mRNA by Hybridization to Oligonucleotide Probes

It is desirable to know if unknown compound "X" is toxic and, if it is, what type of damage it causes to mammalian cells.

HepG2 cells are grown in 165 cm² flasks containing minimal essential medium (Gibco/BRL, Gaithersburg, MD) until they reach a density of approximately 8 x 10⁶ cells/ml. The cells are then subcultured by diluting them to 5 x 10⁶ cells/ml and plated at 10 ml/plate. Several plates of each subculture are exposed to a different concentration of compound X (1 pM to 1 mM in a series of 10-fold dilutions). Messenger RNA is isolated from subcultures after 2, 4, 8, 16 and 32 hours, as described below.

The medium is removed from the cell monolayers by aspiration and the cells are washed twice with cold phosphate buffered saline. I then add 2 ml of cold phosphate buffered saline to the monolayer and use a rubber policeman to scrape the lysate into 15 ml disposable polypropylene tubes. Total RNA was isolated using the RNeasy B reagent (Biotecx Laboratories, Houston, TX), following manufacturer’s directions. The RNA pellet is dried and redissolved in 10 µl water. A normal yield of RNA is about 100-200 µg/plate.

RNA from each two replicate plates is then applied to 20 different slots in a slot blot apparatus as follows. The slot blot apparatus is cleaned prior to use in 0.1 N NaOH. A piece of nitrocellulose paper or nylon membrane filter (0.45µm pore size) is briefly wetted in water and then soaked in 20X SSC for 1 hour at room temperature. The filter is then placed in the
apparatus. The RNA sample from each plate is mixed with 20 µl of 100% formamide, 7 µl of 37% formaldehyde and 2 µl of 20X SSC, incubated at 68°C for 15 minutes and then chilled on ice.

Twenty µg of RNA is applied to each slot in the apparatus together with two volumes of 20X SSC. After the solution drains through the filter, the slots are rinsed twice with 1 ml of 10 X SSC. The filter is then dried and baked at 80°C for 2 hours in a vacuum oven. The filter is then cut into strips so that samples exposed to different concentrations of X for varying periods of time can be hybridized to individual stress gene-specific probes. One strip is used for each separate probe.

Hybridization of the strips to individual oligonucleotide probes are carried out under well known conditions for RNA-DNA hybridization. The temperature and salt concentration for hybridizing various probes to the RNA will depend upon the nature of the oligonucleotide. These conditions can be calculated using well known formulae. Probes to the following genes are used:

- redox stress only: CYP1A1, NM01, ALDH2;
- DNA stress only: XHF, DRA, GADD153 and MDR-1;
- protein stress only: HSP70, MT 1A;
- redox and DNA stress: GST Ya, HMO and MnSOD;
- redox, DNA and protein stress: JUN;
- DNA, protein and energy/ionic stress: FOS.

Following hybridization, the strips are washed, dried and mRNA levels are quantified in one of two ways. In one method, the strips are exposed to X-ray film and hybridization quantified by densitometry. Alternatively the strips are cut into individual slots and subjected to scintillation counting. Actually, both methods can be carried out if the former is performed first.
II. Indirect Quantification of Stress Gene mRNA by Hybridization of cDNA to Oligonucleotide Probes

A. Cross-Linking of Oligonucleotides To Negatively Charged Membrane

We separately cross-linked oligonucleotides homologous to the mRNAs of the following stress and housekeeping genes to Biodyne C membranes (Pall Corporation, East Hills, New York) essentially using the method described in Y. Zhank et al., *Nucleic Acids Res.*, 19, pp. 3929-33 (1991):

redox stress only: CYP1A1, ALDH1;
DNA stress only: GADD153;
protein stress only: HSP70;
redox and protein stress: MTIIA;
redox and DNA stress: HO;
redox, DNA and protein stress: JUN;
DNA, protein and energy/ionic stress: FOS;
control: γ-actin.

The Biodyne C membrane was first rinsed briefly with 0.1 N HCl. We then treated the membrane for 15 minutes with freshly prepared 20% (w/v) EDC (1-ethyl-3-(3-dimethylaminopropylcarbodiimide)). The membrane was then rinsed with H2O and placed on a 96-well Dot-Blot apparatus. We then applied the amino-modified oligonucleotides in 0.5M NaHCO3 (pH 8.4) to the membrane in individual wells using a vacuum for 15 min. The total volume per well should not to exceed 3 μl. Each individual oligonucleotides was applied in four adjacent wells.

After applying the oligonucleotides, we rinsed the membrane with 1 x TBS/0.1% Tween-20 and then quenched any remaining active groups on the membrane by treating with 0.1N NaOH for 10 min. We then rinsed the membrane with dH2O, air dried, and stored the dry membrane in a sealed plastic bag.
B. Treatment of Cells and Isolation of RNA

HepG2 cells are grown in minimal essential medium in 100 mm cell culture dishes to no greater than 80% confluency. The cultures are then exposed to various concentrations of compound X and are incubated at 37°C for the desired length of time. After aspirating off the media, the cells are washed three times with 10 ml of a room temperature phosphate buffered saline solution. 5 ml of the phosphate buffered saline solution is then added to the cell culture dish and the cells are scraped from the dish with a rubber policeman and placed in a 15 ml centrifuge tube. Cells are the counted with a hemacytometer and pelleted in a centrifuge. The phosphate buffered saline is poured off.

If total RNA isolation is desired, we use RNeasy B (Biotecx Laboratories, Inc., Houston, TX), following manufacturer's directions. If only mRNA is desired, the Messenger RNA Isolation Kit (Stratagene Inc., La Jolla, CA) is used, following the manufacturer's directions.

3. Reverse Transcription and Optional PCR of Stress-Specific cDNAs

Total RNA (50 µg) or mRNA (2 µg) isolated by the procedures described above is then reverse transcribed using SUPERSCRIPT II (reverse transcriptase) (Gibco/BRL, Gaithersburg, MD) and the following protocol.

The RNA is added to a microcentrifuge tube with DEPC H₂O and oligo-dT primer. The amount of DEPC H₂O added to the reaction mix is determined after the volumes of the other reagents are determined. The oligo-dT primer (0.5 µg/µl) is added so that the volume is 10% of the total end volume. The reaction mixture
is heated to 70°C for 10 min and then quick-chilled on ice. The following components are added in the order: 5x SUPERSCRIPT first strand buffer (20% of total volume); 0.1M DTT (10% of total volume); 10mM dNTP mix (5% of total volume); SUPERSCRIPT II (5% of total volume). The reaction mixture is centrifuged briefly and then mixed by repeated pipetting. The mixture is incubated at 37°C for 1 hour. 2 μl of RNase A (10 mg/ml) is then added to the reaction mixture and mixed by pipetting. The reaction mixture is then incubated at 37°C for another hour. At the end of incubation, ddH₂O is added to a final volume of 450 μl. The cDNA is precipitated by adding 50 μl of 3M sodium acetate, followed by 1 ml of 100% ethanol. The mixture is then centrifuged for 30 minutes in a microcentrifuge at 12,000 x g. The supernatant is removed and the cDNA resuspended in 100 μl of ddH₂O. 2 μl of the resuspended cDNA is then removed and read in a scintillation counter. A total of 1,000,000 cpms is required for hybridization.

The cDNA may be either radiolabelled through the use of α-³²P dCTP (100 μCi) in the reaction or chemically labelled through the use of digoxigenin-dUTP using the GENIUS 1 kit (Boehringer Mannheim Biochemical, Indianapolis, IN).

If an insufficient quantity of stress gene cDNA is obtained by the above process, PCR may be used for amplification. Reverse transcription is carried out as described above, except that no label is incorporated into the cDNA. Primers based on the published 5' and 3' coding sequences of the desired stress gene are used in the PCR reaction. Amplification of all stress gene cDNAs is carried out in the same reaction tube.

The total cDNA is diluted 1:10 with ddH₂O and 10 μl is used for the PCR reaction. The following
components are then added to produce the indicated final concentration: 1x TAQ buffer (Boehringer Mannheim Biochemical); 300 μM each dNTP; 25 pmol each PCR primer; 2.5 units TAQ polymerase (Boehringer Mannheim Biochemical); dH₂O to a total reaction volume of 50μl. The mixture is mixed by pipetting, followed by a 2 second centrifugation. Two drops of light mineral oil are placed on top of the reaction mixture. PCR is set then carried out for 30 cycles of 1 minute at 95°C; 2 minutes at T_m + 2°C; 3 minutes at 72°C (10 minutes during last cycle). The PCR products are labelled with ³²P that has been incorporated into nested primers via a kinase reaction in a one-cycle PCR reaction.

A nested primer is a primer based on a stress specific nucleotide sequence located inside of the sequences upon which the primers for PCR were based. These primers are synthesized using an oligonucleotide synthesizer or purchased from a commercial contractor. The nested primers are labelled by mixing 1.2 μl (0.5 μg/μl) of nested primer with 1.0 μl of 10x kinase buffer (0.5M Tris, pH 8.2, 0.1M MgCl₂, 50 mM DTT); 5.0 μl α-³²P ATP; 1.0 μl polynucleotide kinase and 1.8 μl dH₂O. The reaction is mixed by pipetting and incubated at 37°C for 1 hour. The reaction is terminated by incubation at 70°C for 10 minutes, followed by a quick centrifugation and cooling on ice. 90 μl of dH₂O are then added, followed by 100 μl of phenol/chloroform (1:1). The mixture is mixed well, centrifuged for 10 minutes, and the aqueous phase is then transferred to a new tube. We then precipitate the labelled primers by adding 10 μl of 3M sodium acetate, 1 μl of 10 mg/ml tRNA, and 400 μl of 100% ethanol and placing on ice for 10 minutes. The mixture is the centrifuged for 30 min at room temperature. The pellet is washed with 80% ethanol, centrifuged for 5 seconds and dried.
pellet is resuspended with 4 µl dH₂O, 0.5 µl 10x TAQ buffer, and 0.5 µl TAQ enzyme.

We then add 5 µl of the labeled nested primers to the aqueous phase of the above-described PCR mixture under the mineral oil and perform an additional cycle of PCR by heating to 95°C for 2 minutes, cooling to Tₘ + 2°C (of labeled primer) for 2 minutes and warming to 72°C for 10 minutes.

We then remove 50 µl of the aqueous phase to a new tube, add 50 µl dH₂O, 100 µl phenol/chloroform, mix well, and centrifuge for 10 minutes. The aqueous phase is recovered into a fresh tube. Unincorporated primers are removed using a spin column.

4. Hybridization

The membrane containing the cross-linked oligonucleotides is wetted in 15 ml of RAPID HYB buffer (Amersham, Arlington Heights, IL) by holding one end of the membrane with a pair of tweezers and slowly immersing the membrane. The membrane is then prehybridized by transferring to a Seal-a-Meal bag, the 15 ml of RAPID HYB buffer from the wetting step is added, and the bag is sealed. It is then immersed in a 68°C shaking water bath for 1 hour. The labeled cDNA (15,000,000 cpms) is diluted into 1 ml of RAPID HYB and boiled for 10 minutes followed by quick-chilling on ice.

After prehybridization, the RAPID HYB is removed and replaced with 14 ml of fresh RAPID HYB preheated to 65°C. The labelled cDNA is then added to the bag and the end is resealed. The bag is then immersed in a 68°C shaking water bath overnight. After hybridization, the membrane is removed from the bag and placed into a tray containing low stringency buffer (2x SSC/0.1% SDS) for 20 minutes at room temperature. The membrane is then transferred to high stringency buffer (0.2x SSC/0.1% SDS; preheated to 45°C), and shaken for
30 minutes at 45°C. The membrane is then removed from the high stringency wash, placed on a piece of Whatman 3MM filter and exposed to X-ray film at -70°C overnight with an intensifying screen. After development, the autoradiograph is cut to fit into a 96-well microtiter plate holder and taped such that the radioactive dots are aligned with the holes in the holder. The autoradiograph is then read at 600nm for quantification.

The results for either of the two above-described assays are then compared to a database of standards prepared using the above promoters and known toxins. By correlating results for X with known compounds, a toxicity profile can be created. For example, if X induced the same stress genes as TCDD at similar concentrations, this would indicated that X is toxic to whole animals at similar concentrations as TCDD.

EXAMPLE 3

**Construction Of Stress Promoter-CAT Fusions**

I prepared an XHF promoter-CAT fusion as follows. I synthesized two oligonucleotides based upon the published sequence of the XHF (collagenase) promoter [P. Angel et al., *Mol. Cell Biol.*, 7, pp. 2256-66 (1987)]. One corresponded to positions -520 to -501 upstream from the transcription start site primer. [SEQ ID NO. 44]: 5’-TACCAGGCAGCTTAACAAAG-3’. The other corresponded to positions +53 to +73 downstream from the transcriptions start site. [SEQ ID NO. 45]:

5’-ACTGGCCTTTGCTTCTTTC-3’. The oligonucleotides were synthesized by Operon Technologies (Alameda, CA). The oligonucleotides were dissolved in water at a final concentration of 500 pmoles/ml.
For XHF promoter amplification I mixed 0.1 μg of Raji (human genomic library) genomic DNA, 20 pmoles of each of the above two primers, 5 μl of 10X buffer [500 mM KCl, 100 mM Tris-HCl, pH 8.3, 15 mM MgCl₂, 0.1% gelatin], 5 μl of 2.0 mM of each dNTP and 1 unit of AMPLITAQ (Taq polymerase) (Perkin-Elmer, Norwalk, CT). I added water to a total volume of 50 μl and performed PCR.

The PCR reaction was run at 94°C for 2 minutes, followed by 30 cycles of: 10 seconds at 56°C, 30 seconds at 71°C and 10 seconds at 94°C. The PCR reaction was completed by incubating the mixture at 56°C for 1.5 minutes followed by 71°C for 4 minutes. The reaction product was then electrophoresed on a 1.0% agarose gel and the amplified sequence excised from the gel and purified. The isolated fragment was then kinased and blunt-end ligated into the pBLCAT3 vector described in B. Luckow et al., Nucl. Acids Res., 15, p. 5490 (1987), the disclosure of which is herein incorporated by reference.

Other stress promoter-CAT fusions may be similarly prepared using any of the above-cited, published nucleotide sequences of the various stress gene promoter regions to design appropriate oligonucleotide primers for PCR. CAT fusions with the following stress promoters were prepared for use in the kits and methods of this invention: XHF, CYPIA1, GST Ya, MTIIIA, FOS, HSP70, GADD45, GADD153 and JUN.

EXAMPLE 4

Construction Of A Response Element-CAT Fusion

I constructed a xenobiotic response element XRE-CAT fusion as follows. I first had oligonucleotides corresponding to both strands of the XRE synthesized by an independent contractor (Operon Technologies, Inc., Alameda, CA). The sequence of the
XRE is described in M. Denison et al., *J. Biol. Chem.*, 263, pp. 17221-24 (1988). The oligonucleotides were synthesized with overhanging BamHI compatible ends.

The oligonucleotides were dissolved in water at a final concentration of 500 pmoles/ml. I then mixed 50 µg of each oligonucleotide together in a solution containing 500 mM NaCl, 50 mM Tris-HCl, pH 7.8, 1 mM EDTA and boiled for 5 minutes. I then incubated the solution overnight at 68°C to allow the strands to anneal to one another. The double stranded oligos were then electrophoresed on a 12% polyacrylamide gel and purified by excising the band and electroluting the DNA.

The purified response elements were then kinased and cloned into the BamHI site of pBLCAT2 [M. Denison et al., *J. Biol. Chem.*, 263, pp. 17221-24 (1988)], just upstream of the tk minimal promoter.

Other response element-CAT fusions may be similarly prepared using any of the above-cited, published nucleotide sequences of the various response elements to design appropriate oligonucleotide primers for PCR. CAT fusions with the following response elements were prepared for use in the kits and methods of this invention: XRE, NFkB, CRE, p53RE and RARE

**EXAMPLE 5**

**Assay Of Toxins Using Stress Promoter-CAT Fusions**

Approximately 5 x 10^4 cells of each of the 14 transformed strains described in Example 3 and 4 above were separately plated into a row of 12 wells in one of two 96-well plates. An untransformed human liver cell line was plated into the wells of the last row of the second plate to determine cell viability. The cells were grown in 10% Complete Minimal Essential Media (Gibco/BRL, Gaithersburg, MD) at 37°C, 5% CO₂, until reaching 90% confluency.
We tested five or six different concentrations of the various chemicals listed in Table 3, below, dissolved in the appropriate solvent in triplicate.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Solvent</th>
<th>Concentration Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>3-MC</td>
<td>DMSO</td>
<td>1 nM - 10 μM</td>
</tr>
<tr>
<td>Sodium arsenate</td>
<td>water</td>
<td>1 nM - 10 μM</td>
</tr>
<tr>
<td>DMSO</td>
<td>none</td>
<td>.001 - 10% (v/v)</td>
</tr>
<tr>
<td>Cadmium sulfate</td>
<td>water</td>
<td>100 nM - 10 μM</td>
</tr>
<tr>
<td>Benzo(a)pyrene</td>
<td>DMSO</td>
<td>10 nM - 100 μM</td>
</tr>
<tr>
<td>Ethanol</td>
<td>none</td>
<td>.001 - 10% (v/v)</td>
</tr>
<tr>
<td>PMA</td>
<td>ethanol</td>
<td>3.2 - 200 ng/ml</td>
</tr>
<tr>
<td>MMS</td>
<td>water</td>
<td>10 ng/ml - 100 μg/ml</td>
</tr>
<tr>
<td>Methapyriline</td>
<td>water</td>
<td>10 nM - 100 μM</td>
</tr>
<tr>
<td>TCDD</td>
<td>DMSO</td>
<td>1 nM - 10 μM</td>
</tr>
<tr>
<td>Retinoic acid</td>
<td>DMSO</td>
<td>10 nM - 100 μM</td>
</tr>
</tbody>
</table>

The various concentrations were made by performing a dilution series. For TCDD, we first removed 20 μl of media from each well in columns 3 through 10 and 10 μl from columns 11 and 12 of the 96 well plates. We placed 10 μl of a 200 μM solution of test chemical into each well in columns 11 and 12. The liquid in those wells was mixed well with a multichannel pipetman using separate pipette tips for each row, and 20 μl was then transferred from the wells in column 12 to column 10. The liquid in column 10 was mixed and 20 μl then transferred to column 8 and the procedure repeated for the even numbered columns down to column 4. The same
procedure was carried out for the odd numbered columns starting with column 11 and ending with column 3. Columns 1 and 2 of each row represent untreated controls. The plates were then incubated at 37°C, 5% CO₂ overnight.

At the end of the incubation the media was gently aspirated from all of the wells except the cell viability row on the second plate. The cells in all but that last row were washed twice with 200 µl of phosphate buffered saline. After the wash, we added 100 µl of Cell Lysis Buffer (5 mM Mops, 2.5 mM NaCl, 0.38 mM MgCl₂, 0.25% Triton X-100, pH to 6.5 using NaOH) to each well and incubated 30 minutes at room temperature. We then combined the lysates in the wells containing duplicate concentrations of chemical by transferring the 100 µl of lysate in column 12 to column 11, column 10 to column 9, and so on.

We assayed the total protein in each well as follows. In two fresh 96 well plate we added 190 µl of 1X Protein Assay Reagent (Bio-Rad Laboratories, Hercules, CA) to each well in column 1 through 7. We transferred 10 µl of cell lysate from the wells in column 1 of the toxin test plate to column 2 of the protein assay plate, from column 3 of the toxin test plate to column 3 of the protein assay plate, from column 5 of the toxin test plate to column 4 of the protein assay plate and so on. The plates were then incubated for 15 minutes at room temperature and then the absorbance of each well read at OD₆₀₀.

The CAT assay was performed using a CAT ELISA kit (5 Prime-3 Prime, Inc., Boulder, CO) and following the manufacturer’s directions. We used 190 µl of each cell lysate in the toxin test plates for determining CAT activity. The CAT assay was allowed to proceed for three and one-half hours at room temperature. CAT activity was measured by using a biotinylated anti-CAT
-60-

antibody, followed by a streptavidin conjugated
alkaline phosphatase, and finally the colorimetric
substrate, p-nitrophenyl-phosphate. Color development
was measured at OD_{405}.

5 Fold-induction was calculated using the
following formula:

\[
\frac{\text{OD}_{405}(\text{test sample})}{\text{OD}_{405}(\text{control})} \times \frac{\text{OD}_{600}(\text{test sample})}{\text{OD}_{600}(\text{control})}
\]

10 The results for each of these experiments is
shown graphically in Figures 1 - 11.

EXAMPLE 6

Identification Of Antitoxins

15 After an unknown compound is found to be a
toxin on the basis of its induction of one or more
mammalian stress promoters, the same process can be
utilized to identify a potential antitoxin.

An unknown compound is demonstrated to induce
the HMO promoter and the GADD153 promoter in any of the
assays described herein. This indicates that the
compound is causing oxidative stress and DNA damage.
One possibility is that the compound is causing
hydrogen peroxide formation in sufficiently high
amounts to result in DNA strand breaks. Ascorbic acid
is known to reduce the number of hydrogen peroxide-
induced DNA strand breaks, and therefore is a potential
antitoxin to this unknown compound.

HepG2 cells are grown as described in Example
2. The cells are then incubated with varying
dilutions of ascorbic acid for 30 minutes. The cells
are then exposed to the concentration of unknown
compound previously determined to be optimum for
inducing the HMO and GADD153 promoters. The assay for
promoter induction (and concomitant stress gene
expression) is then carried out as described in Example
2. If the ascorbic acid-treated cells produce a lower
level of HMO or GADD153 mRNA transcripts than control
cells, it is considered to be an antitoxin.

While I have hereinbefore presented a number
of embodiments of this invention, it is apparent that
my basic construction can be altered to provide other
embodiments which utilize the diagnostic kits, pro-
cesses and products of this invention. Therefore, it
will be appreciated that the scope of this invention is
to be defined by the claims appended hereto rather than
the specific embodiments which have been presented
hereinbefore by way of example.
_SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: XenometirX, Inc. (all states except US)
   2860 Wilderness Place
   Suite 150
   Boulder, Colorado 80301
   United States of America

(ii) APPLICANT: Farr, Spencer B (US only)
    2852 Kalmia Avenue
    No. 184
    Boulder, Colorado 80301
    United States of America

(iii) APPLICANT: Todd, Marque D (US only)
     8200 North Sheridan Boulevard
     No. 904
     Westminster, Colorado 80003
     United States of America

(ii) TITLE OF INVENTION: METHODS AND DIAGNOSTIC KITS UTILIZING
     EUKARYOTIC STRESS PROMOTERS TO DETERMINE TOXICITY OF A
     COMPOUND

(iii) NUMBER OF SEQUENCES: 45

(iv) CORRESPONDENCE ADDRESS:
    (A) ADDRESSEE: James F. Haley, Jr.
    (B) STREET: 1251 Avenue of the Americas
    (C) CITY: New York
    (D) STATE: New York
    (E) COUNTRY: United States of America
    (F) ZIP: 10020

(v) COMPUTER READABLE FORM:
    (A) MEDIUM TYPE: Floppy disk
    (B) COMPUTER: IBM PC compatible
    (C) OPERATING SYSTEM: PC-DOS/MS-DOS
    (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:
    (A) APPLICATION NUMBER:
    (B) FILING DATE:
    (C) CLASSIFICATION:

(vii) PRIOR APPLICATION DATA:
    (A) APPLICATION NUMBER: US 08/008,896
    (B) FILING DATE: 21-JAN-1993

(viii) ATTORNEY/AGENT INFORMATION:
    (A) NAME: Marks, Andrew S
    (B) REGISTRATION NUMBER: 33,259
    (C) REFERENCE/DOCKET NUMBER: X-1 CIP

(ix) TELECOMMUNICATION INFORMATION:
    (A) TELEPHONE: (212) 596-9000
    (B) TELEFAX: (212) 596-9090
    (C) TELEX: 14-8367

(2) INFORMATION FOR SEQ ID NO:1:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 70 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
AAAAAAACCC AGTCCAACTA CAGACATGGC AGCTGAGTCC CTGCCATTCA CCTTGGAGAC 60
GGTGTHTTTT 70

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 69 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
AAAAAAAGGCC AGTATGCACTA CCTTTCCTCC ACTGCTGCTG CTGCTGTTCT GGGGTGTGQT 60
GTCTTTTTT 69

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 59 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
AAAAAACCC AAGATCTCTGT AACAGAAGCAT GACCTGGAAC CTGGCGGACC CAGTTTTTTT 59

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 63 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
AAAAAAACAAC CTGAACGTCA ACGAGGAGAA GTACCAGGAG GCATTGGCCA AGGGAGATTTT 60
TTT 63

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 60 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
AAAAAATAGA CGTCCGCAA CCCGACACCA TGCCCCAGGA TTTGTCAGAG GCCCTTTTTT 60
(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 65 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

AAAAAAGGGG TTTTTTTTTT AGTTGGAGAAAGGACCGAC TCTGCTCTAG TCAGTACTCT 60

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 69 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAAAAAGCCG CGGCGTCCG CACGACCTG GGCACCACCT ACTCCTGCGT GGGGCTTTC 60
CAATTTTTTT 69

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 62 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

AAAAAATTA CAGCAACCT GGAACCTATA GCCCCTTTAA CTGAGACGAC ATCATTTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 62 base pairs
    (B) TYPE: nucleic acid
    (C) STRANDEDNESS: single
    (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

AAAAAACTTTT CAGCAAGGCT TTGGGCTAGCT AGGGAAGGAT AAGGTGAGAG TCAGCCTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 62 base pairs

(E) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AAAAAAATGC TGGAGAAGGA GTCTGCGGCT GAGTGGTAGT AAGAGAGGCT ATCCCCCTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

AAAAAAGGAA TCTCATTTC TAGCTTTGTG CTGGTTTCTA GTTGGATGG ACTTGGCTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

AAAAAACCTC TTGCTTCCCC GTGTTTAGGT AGCCGAGGAT CTTCTTAAAAC TGAGTTTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

AAAAAAACGT GGTCATATGTC ACGTGGCTTC GAAATGGAAA ACCTGTCACC ACAGGATTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 69 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
AAAAGGGT TGTGAAATGA AACGCACCAC ACTGGACAGC CCGTTGGGGA AGCTGGAGCT  60
GTCTTTTTT  69

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:
AAAATTTTCT TACAATTTTG GTACCAGTG C TGTGACTAGGC GGATGGAGCT CTTGAGTTTT  60
TT  62

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:
AAAAGGTCT TTGATAGAC CTGTGCACAA ATAGTTAAG ATGGCCTGGG TGATTCTTTT  60
TT  62

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 51 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:
AAAAACCCAG CACCCGGCTT CCGGACTAC TTTATAGGC CCAGACTTTTT T  51

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:
AAAAAAACCC GTACTCTCCC AGTTCTCCTC CATTCCAGA CATCTTGAAAT CCACCATTTT  60
TT  62

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:
AAAAAGAGT GTCTTTGCGA TACTTGATCA CCAAGGCACCT GTACTGAGCA ATCTGGTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:
AAAAAAAAAC ACCTTCTCTCA CATCATCAGC ACTCTTTTTC TTCAGGGCGA CCATTTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:
AAAAAGAAG CTCTCAGACA CCAAGTAGAC TGACTGGATCG TTCAGGGTCTT GGGAGGTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
AAAAAAAAACTCA GAATATAGGC AGCCAGGCC ACAGGAGAGT CATCAGAGC AGAGCCTTTT
TT 62

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:
AAAAAGAGAT GCCCTTCTCT TCCAGACCATT TCCACTTCTG TTCTCTCTCT TTCTCTCTTT
TT 62
(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 62 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(x) SEQUENCE DESCRIPTION: SEQ ID NO:24:
AAAAAGCCT CTGCCAGTTT TTCTTCAGTC ATCTTCACA ACAAATTCAC AGTGGTTTTT 60
TT 62

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 67 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(x) SEQUENCE DESCRIPTION: SEQ ID NO:25:
AAAAAAATCTC TTCTTCAGCT GGCTTGCTTG CACCTGCAGT GCCTGCCTGC AATGCAAAGA 60
GGTTTTTT 67

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(x) SEQUENCE DESCRIPTION: SEQ ID NO:26:
AATTGCTATG GGCCTGTTAAG TGCCCGATGT CCCTTTGTTG GATTCAAGAT 50

(2) INFORMATION FOR SEQ ID NO:27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(x) SEQUENCE DESCRIPTION: SEQ ID NO:27:
ATCTGAGTTC CTACCTGAAC GGTCTTCTAC CCCCCGATGGT GCTATGACA

(2) INFORMATION FOR SEQ ID NO:28:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 45 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:
GTACTCCCA G TGACTGCT TACAGTTCTT C TCTCTCTT CACCT

(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 50 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
AGGAGATGA AAGGAAAGTG GCACAGCTAG CTGAAGAGAA TGAACGGCTC

(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 50 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
AGTCGCTACA TGGATCAAAG GGTCTCCAGTG ATTAATCTCC CTGAACGGTG

(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 50 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
GTGGTGACC TGACCTGCCG TCTAGAAAAA CCTGCCAAAT ATGATGACRT 50

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 50 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
CAGCCCCAAGG AAGCCCTCCA TGATGAGAA ATCTTTAGAA GAAGCAAGGA 50

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 44 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
CTTACACTCA GCTTTCTGGT GCCGACAGTT GCTGGAGGGC TTTA 44

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 45 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
AGAAGGACGA GTTGAGGCAC AAGAGGAAGG AGCTGGAGCA GGTGT 45
(2) INFORMATION FOR SEQ ID NO:35:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:
GCTCAGGGAA CAGGTGGCAG AGCTTTAACA GAAGAATCGT AACCACGGTA 50

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:
GAAAGGCTAC TATTTTCAAA TGTCAGTGTA CCAGGCTGGA ACAAAGCAGC 50

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:
GCACTGGCCTC TGGCAATGC AAAGAGTGCA AATGCAACTC CTGCAAG 47

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA
(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:
CCCAGGGCTG CATCTGCAA A GGCCGGTCCG ACAAG

(2) INFORMATION FOR SEQ ID NO:39:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:
ACCACGTAT TTTGCTCAA GGCACCCCTT TGACCTAAAC TTCCAGGCAG

(2) INFORMATION FOR SEQ ID NO:40:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:
ACAAAAAGCCA CTCCA C TCTC TCAACGGTG ACACTCAGTA TUTCTGCAGA

(2) INFORMATION FOR SEQ ID NO:41:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 50 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:
TTGCTCTCGA CAGTATCCAC AATAGCTGAC GGCTGGGTGT T TACAGTTTGA

(2) INFORMATION FOR SEQ ID NO:42:
(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 45 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:
ACCTTCAGC AGATGGGAT TAGCAAGCAG GAGTACGACG AGTCG

(2) INFORMATION FOR SEQ ID NO:43:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 50 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:43:
TTGAGTGGAT CCCCAACAAT GTGAAAACGG CTGTCTGTGA CATCCACCT

(2) INFORMATION FOR SEQ ID NO:44:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:44:
TACCAGGCAG CTTAACAAG

(2) INFORMATION FOR SEQ ID NO:45:

(i) SEQUENCE CHARACTERISTICS:
   (A) LENGTH: 20 base pairs
   (B) TYPE: nucleic acid
   (C) STRANDEDNESS: single
   (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:45:
ACTGGCCTTT GTCTTCTTTC
I claim:

1. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell characterized by:
      (i) at least one promoter which responds to redox stress;
      (ii) at least one promoter which responds to DNA stress;
      (iii) at least one promoter which responds to protein stress; and
      (iv) at least one promoter which responds to energy/ionic stress,
   each of said promoters being operatively linked to a different gene which encodes a detectable product; and
   (b) at least four different nucleic acid sequences, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked to said promoters or to a single stranded cdDNA prepared from said mRNA transcript.

2. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell comprising at least 4 different promoters which respond to redox stress, each of said promoters being operatively linked to a gene which encodes a different detectable product; and
   (b) at least four different nucleic acid sequences, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked
to said promoters or to a single stranded cDNA prepared from said mRNA transcript.

3. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell comprising at least 4 different promoters which respond to DNA stress, each of said promoters being operatively linked to a different gene which encodes a detectable product; and
   (b) at least four different nucleic acid sequences, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked to said promoters or to a single stranded cDNA prepared from said mRNA transcript.

4. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell comprising at least 4 different promoters which respond to protein stress, each of said promoters being operatively linked to a different gene which encodes a detectable product; and
   (b) at least four different nucleic acid sequences, each of said nucleic acid sequences being capable of hybridizing to the mRNA transcript of a different one of the genes that is operatively linked to said promoters or to a single stranded cDNA prepared from said mRNA transcript.

5. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell comprising at least 4 different promoters which respond to energy/ionic stress, each of said promoters being
operatively linked to a different gene which encodes a
detectable product; and

(b) at least four different nucleic
acid sequences, each of said nucleic acid sequences
being capable of hybridizing to the mRNA transcript of
a different one of the genes that is operatively linked
to said promoters or to a single stranded cDNA prepared
from said mRNA transcript.

6. A diagnostic kit for identifying and
characterizing a toxic compound comprising:

(a) a mammalian cell comprising at
least 3 different promoters which respond to cell
surface receptor stress, each of said promoters being
operatively linked to a different gene which encodes a
detectable product; and

(b) at least three different nucleic
acid sequences, each of said nucleic acid sequences
being capable of hybridizing to the mRNA transcript of
a different one of the genes that is operatively linked
to said promoters or to a single stranded cDNA prepared
from said mRNA transcript.

7. The diagnostic kit according to claim 1,
wherein said eukaryotic cell is a mammalian cell which
additionally comprises a promoter which responds to
cell surface receptor-mediated stress, said promoter
being operatively linked to a gene which encodes a
detectable product, said kit additionally comprising at
least one nucleic acid sequence which is capable of
hybridizing to either the mRNA transcript of said gene
which is operatively linked to said cell surface
receptor-mediated promoter or a single stranded cDNA
reverse transcribed from the mRNA transcript of each of
said genes.
8. A diagnostic kit for identifying and characterizing a toxic compound comprising:
   (a) an eukaryotic cell which harbors at least one promoter or response element that
       responds to redox stress;
   (b) an eukaryotic cell which harbors at least one promoter or response element that
       responds to DNA stress;
   (c) an eukaryotic cell which harbors at least one promoter or response element that
       responds to protein stress; and
   (d) an eukaryotic cell which harbors at least one promoter or response element that
       responds to energy/ionic stress;
wherein, each of said promoters or response elements is operatively linked to a heterologous gene encoding a detectable product.

9. A diagnostic kit for identifying and characterizing a toxic compound comprising at least 4 different eukaryotic cells, each of which harbors a different promoter or response element that responds to redox stress and is operatively linked to a heterologous gene encoding a detectable product.

10. A diagnostic kit for identifying and characterizing a toxic compound comprising at least 4 different eukaryotic cells, each of which harbors a different promoter or response element that responds to DNA stress and is operatively linked to a heterologous gene encoding a detectable product.

11. A diagnostic kit for identifying and characterizing a toxic compound comprising at least 4 different eukaryotic cells, each of which harbors a different promoter or response element that responds to
protein stress and is operatively linked to a heterologous gene encoding a detectable product.

12. A diagnostic kit for identifying and characterizing a toxic compound comprising at least 4 different eukaryotic cells, each of which harbors a different promoter or response element that responds to energy/ionic stress and is operatively linked to a heterologous gene encoding a detectable product.

13. A diagnostic kit for identifying and characterizing a toxic compound comprising at least 3 different eukaryotic cells, each of which harbors a different promoter or response element that responds to cell surface receptor-mediated stress and is operatively linked to a heterologous gene encoding a detectable product.

14. The diagnostic kit according to claim 8, additionally comprising a mammalian cell harboring a promoter which responds to cell surface receptor-mediated stress, said promoter being operatively linked to a heterologous gene encoding a detectable product.

15. The diagnostic kit according to any one of claims 1-5 or 8-12, wherein said eukaryotic cell is a mammalian cell.

16. The diagnostic kit according to claim 15, wherein said mammalian cell is a HepG2 cell.

17. The diagnostic kit according to any one of claims 6-7 or 13-14, wherein said mammalian cell is a cell derived from the skin or from the eye.
18. The diagnostic kit according to any one of claims 1, 2, 7, 8, 9 or 14 wherein said promoter or response element that responds to redox stress is selected from CYPIA1, GST Ya, JUN, XRE, NFkBRE, RARE, ThRE, PPRE, ERE, NMO1, ALDH1, ALDH2, HMO, MnSOD, UGT, CYP11B2, Cu.ZnSOD, ADPRT, GP, FAOxase, PBE, PPAR, EH, CYP2B2, CYP2E1, CYP3A3, P450b, P450d, PPa, PKC, GST2, GAPDH, NQO or ARE.

19. The diagnostic kit according to any one of claims 1, 3, 7, 8, 10 or 14, wherein said promoter or response element which responds to DNA stress is selected from GST Ya, GADD45, JUN, FOS, XHF, GADD153, TRE, p53RE, HMO, DRA, MnSOD, MDR-1, EGR-1, GAS 2,3, MGMT, DNA Pol, beta-pol, DHFR, TK, PCNA, PGHS, LOX, ISG15, 2'-5' AS, EH, CYP2E1, TP01, TPO2, PCNA or PPa.

20. The diagnostic kit according to any one of claims 1, 4, 7, 8, 11 or 14, wherein said promoter or response element which responds to protein stress is selected from GRP78, JUN, FOS, HSP70, MT 1A, MT IIA, MT III or GP.

21. The diagnostic kit according to any one of claims 1, 5, 7, 8, 12 or 14, wherein said promoter which responds to energy/ionic stress is selected from GRP78, FOS, CRE, CYP11B2, 2'-5' AS, TH, DBH, ODC, CYP2E1, G6PD, PKC or PVALB.

22. The diagnostic kit according to any one of claims 6, 7, 13 or 14, wherein said promoter which responds to cell surface receptor-mediated stress is selected from IL-1 alpha, G-CSF, GM-CSF, TNF alpha, IL-3, IL-8, IL-6, ICAM-1, IL-10 and M-CSF.

23. The diagnostic kit according to claim 1,
wherein: said promoters comprise ALDH1, CYP1A1, FOS, GADD153, HMO, HSP70, JUN and MTIIA; and said eukaryotic cell is a HepG2 cell.

24. The diagnostic kit according to claim 8, wherein: said promoters or response elements comprise CYP1A1, GST Yα, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE and p53RE; and said eukaryotic cells are HepG2 cells.

25. The diagnostic kit according to claim 24, wherein said gene encoding a detectable product is the CAT gene.

26. A method for determining the toxicity of a compound comprising the steps of:

(a) culturing:

(i) a eukaryotic cell comprising at least one promoter or response element which responds to redox stress;

(ii) a eukaryotic cell comprising at least one promoter or response element which responds to DNA stress;

(iii) a eukaryotic cell comprising at least one promoter or response element which responds to protein stress; and

(iv) a eukaryotic cell comprising at least one promoter or response element which responds to energy/ionic stress;

wherein each of said promoters or response elements is operatively linked to a gene encoding a detectable product;

(b) exposing said cells to said compound; and

(c) detecting the product of each of said genes.
27. A method for determining the toxicity of a compound comprising the steps of:
   (a) culturing:
       (i) a eukaryotic cell harboring a first redox stress promoter or response element operatively linked to a gene encoding a detectable product;
       (ii) a eukaryotic cell harboring a second redox stress promoter or response element operatively linked to a gene encoding a detectable product;
       (iii) a eukaryotic cell harboring a third redox stress promoter or response element operatively linked to a gene encoding a detectable product;
       (iv) a eukaryotic cell harboring a fourth redox stress promoter or response element operatively linked to a gene encoding a detectable product;
   (b) exposing said cells to said compound; and
   (c) detecting the product of each of said genes.

28. A method for determining the toxicity of a compound comprising the steps of:
   (a) culturing:
       (i) a eukaryotic cell harboring a first DNA stress promoter or response element operatively linked to a gene encoding a detectable product;
       (ii) a eukaryotic cell harboring a second DNA stress promoter or response element operatively linked to a gene encoding a detectable product;
(iii) a eukaryotic cell harboring a third DNA stress promoter or response element operatively linked to a gene encoding a detectable product;

(iv) a eukaryotic cell harboring a fourth DNA stress promoter or response element operatively linked to a gene encoding a detectable product;

(b) exposing said cells to said compound; and

(c) detecting the product of each of said genes.

29. A method for determining the toxicity of a compound comprising the steps of:

(a) culturing:

(i) a eukaryotic cell harboring a first protein stress promoter or response element operatively linked to a gene encoding a detectable product;

(ii) a eukaryotic cell harboring a second protein stress promoter or response element operatively linked to a gene encoding a detectable product;

(iii) a eukaryotic cell harboring a third protein stress promoter or response element operatively linked to a gene encoding a detectable product;

(iv) a eukaryotic cell harboring a fourth protein stress promoter or response element operatively linked to a gene encoding a detectable product;

(b) exposing said cells to said compound; and

(c) detecting the product of each of said genes.
30. A method for determining the toxicity of a compound comprising the steps of:
   (a) culturing:
      (i) a eukaryotic cell harboring a first energy/ionic stress promoter or response element operatively linked to a gene encoding a detectable product;
      (ii) a eukaryotic cell harboring a second energy/ionic stress promoter or response element operatively linked to a gene encoding a detectable product;
      (iii) a eukaryotic cell harboring a third energy/ionic stress promoter or response element operatively linked to a gene encoding a detectable product;
      (iv) a eukaryotic cell harboring a fourth energy/ionic stress promoter or response element operatively linked to a gene encoding a detectable product;
   (b) exposing said cells to said compound; and
   (c) detecting the product of each of said genes.

31. A method for determining the toxicity of a compound comprising the steps of:
   (a) culturing:
      (i) a mammalian cell harboring a first cell surface receptor-mediated stress promoter or response element operatively linked to a gene encoding a detectable product;
      (ii) a mammalian cell harboring a second cell surface receptor-mediated stress promoter or response element operatively linked to a gene encoding a detectable product;
(iii) a mammalian cell harboring a third cell surface receptor-mediated stress promoter or response element operatively linked to a gene encoding a detectable product;
(b) exposing said cells to said compound; and
(c) detecting the product of each of said genes.

32. The method according to claim 26, comprising the additional step of culturing a mammalian cell comprising at least one promoter or response element which responds to cell surface receptor-mediated stress.

33. The method according to any one of claims 26-32, wherein:
(a) each of said promoters or response elements is operatively linked to the same gene encoding a detectable product, said gene being heterologous to each of said promoters or response elements; and
(b) each of said cells harbors a different promoter or response element operatively linked to said gene and is cultured separately prior to exposure to said compound.

34. The method according to any one of claims 26-30, wherein said eukaryotic cell is a mammalian cell.

35. The method according to claim 31 or 32, wherein said mammalian cell is derived from the skin or the eye.
36. The method according to claim 33, wherein said cell is a mammalian cell.

37. The method according to claim 34, wherein said mammalian cell is HepG2.

38. The method according to any one of claims 26, 28 or 32, wherein said promoter or response element that responds to redox stress is selected from CYP1A1, GST Ya, JUN, XRE, NFKBRE, RARE, ThRE, PPRE, ERE, NMO1, ALDH1, ALDH2, HMO, MnSOD, UGT, CYP11B2, Cu.ZnSOD, ADFRT, GP, FAoxase, PBE, PPAR, EH, CYP2B2, CYP2E1, CYP3A3, P450b, P450d, Ppa, PKC, GST2, GAPDH, NQO or ARE.

39. The method according to any one of claims 26, 29 or 32, wherein said promoter or response element that responds to DNA stress is selected from GST Ya, GADD45, JUN, FOS, XHF, GADD153, TRE, p53RE, HMO, DRA, MnSOD, MDR-1, EGR-1, GAS 2,3, MGMT, DNA Pol, beta-pol, DHFR, TK, PCNA, PGHS, LOX, ISG15, 2'-5' AS, EH, CYP2E1, TPO1, TPO2, PCNA or PPa.

40. The method according to any one of claims 26, 30 or 32, wherein said promoter or response element that responds to protein stress is selected from GRP78, JUN, FOS, HSP70, MT 1A, MT IIA, MT III or GP.

41. The method according to any one of claims 26, 31 or 32, wherein said promoter or response element that responds to energy/ionic stress is selected from GRP78, FOS, CRE, CYP11B2, 2'-5' AS, TH, DBH, ODC, CYP2E1, G6PD, PKC or PVALB.
42. The method according to any one of claims 26, 27 or 32, wherein said promoter or response element that responds to cell surface receptor-mediated stress is selected from IL-1 alpha, G-CSF, GM-CSF, TNF alpha, IL-3, IL-8, IL-6, ICAM-1, IL-10 and M-CSF.

43. The method according to claim 26, wherein the detection of said gene products comprises the steps of:

   (a) isolating mRNA from said exposed culture;

   (b) quantitating the amount of mRNA transcribed from each of said genes that is operatively linked to a stress promoter or response element.

44. The method according to claim 36, wherein said gene encoding a detectable product is the CAT gene.

45. The method according to any one of claims 26-30 or 32, comprising the additional step of incubating said compound with an S9 liver extract prior to exposing said cells to said compound.

46. The method according to claim 44, wherein:

   said promoters or response elements comprise CYPIA1, GST Yα, GADD45, FOS, XHF, HSP70, MT IIA, GADD153, CRE, XRE, NFkBRE, RARE and p53RE; and

   said mammalian cells are HepG2 cells.

47. A method of identifying an antitoxin to a new toxic compound comprising the steps of:

   (a) determining the types of stresses caused by said new toxic compound by the method according to any one of claims 26-46;
(b) identifying a known toxic compound which, in the process according to any one of claims 26-46, causes stresses similar to those caused by said toxic compound; and

(c) repeating the method used to determine the types of stresses caused by said new toxic compound according to step (a) with the additional step of treating the eukaryotic cells employed in said method with an antitoxin to said known toxic compound identified in step (b).

48. A method of decreasing the toxicity of a drug, comprising the steps of:

(a) determining the type of stresses caused by said drug using the methods according to any one of claims 26 to 46; and

(b) modifying said drug to alter or eliminate the portion thereof suspected of causing said determined stresses.

49. The method according to claim 48, further comprising, after step (b), the additional step of:

(c) repeating the method used to determine the types of stresses caused by said drug according to step (a) using the modified drug according to step (b).

50. A modified drug produced by the method according to claim 49 or 50.
FIGURE 2
3-Methyl cholangrene

Fold Induction

GADD45, GADD153, RARE, P53RE, CRE, HSP70, NFkB, XRE, FOS, HMT1A, GSTP1, CYP1A1

Concentration:
- 10 uM
- 1 uM
- 100 nM
- 10 nM
- 1 nM
- 0 nM
FIGURE 4
Cadmium Sulfate

Fold Induction
FIGURE 11
All Trans Retinolic Acid
A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 C12Q1/68 //C12N15/85

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
IPC 5 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>EP, A, 0 325 849 (SALK INSTITUTE FOR BIOLOGICAL STUDIES) 2 August 1989 see page 15, line 15 - line 44</td>
<td>1-46</td>
</tr>
<tr>
<td>X</td>
<td>WO, A, 92 05286 (BRENT ET AL.) 2 April 1992 see the whole document</td>
<td>1-46</td>
</tr>
<tr>
<td>X</td>
<td>WO, A, 90 10710 (DELTA BIOTECHNOLOGY LTD) 20 September 1990 see the whole document</td>
<td>1-46</td>
</tr>
<tr>
<td>X</td>
<td>EP, A, 0 516 443 (ELI LILLY AND CO) 2 December 1992 see the whole document</td>
<td>1-46</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of box C. | Patent family members are listed in annex.

Special categories of cited documents:

*A* document defining the general state of the art which is not considered to be of particular relevance

*E* earlier document but published on or after the international filing date

*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

*O* document referring to an oral disclosure, use, exhibition or other means

*P* document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search: 8 June 1994

Date of mailing of the international search report: 24. 06. 94

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Ajmerich
Tel. (+ 31-70) 340-2060, Tx 31 651 epo nl, Fax (+ 31-70) 340-3016

Authorized officer: Molina Galan, E
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
| A        | MOLECULAR AND CELLULAR BIOLOGY  
vol. 2, no. 9, September 1982,  
WASHINGTON US  
pages 1044 - 1051  
GORMAN ET AL. 'Recombinant genomes which  
express CAT in mammalian cells'  
see the whole document | 1-46 |
| P,A      | WO,A,94 01584 (PRESIDENT AND FELLOWS OF  
HARVARD COLLEGE) 20 January 1994  
cited in the application  
see the whole document | 1-50 |
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>AU-B- 628312</td>
<td>17-09-92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 2818889</td>
<td>05-07-89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU-A- 3026892</td>
<td>22-04-93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 3503597</td>
<td>15-08-91</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO-A- 8905355</td>
<td>15-06-89</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US-A- 5274077</td>
<td>28-12-93</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA-A- 2092060</td>
<td>25-03-92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN-A- 1065092</td>
<td>07-10-92</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP-T- 6503713</td>
<td>28-04-94</td>
</tr>
</tbody>
</table>